Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3598123 A
Publication typeGrant
Publication dateAug 10, 1971
Filing dateApr 1, 1969
Priority dateApr 1, 1969
Publication numberUS 3598123 A, US 3598123A, US-A-3598123, US3598123 A, US3598123A
InventorsAlejandro Zaffaroni
Original AssigneeAlza Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Bandage for administering drugs
US 3598123 A
Images(1)
Previous page
Next page
Description  (OCR text may contain errors)

United States Patent [72] Inventor Alejandro Zaflaroni Atherton, C851. [21] Appl. No. 812,117 [22] Filed Apr. 1, 1969 [45] Patented Aug. 10, 1971 [73] Assignee ALZA Corporation [54] BANDAGE FOR ADMINIS'IERING DRUGS 13 Claims, 2 Drawing Figs.

[52] US. Cl 128/268, 424/20, 424/28 [51] Int. Cl. A61! 7/02 [50] FieldoISear-ch 1. 128/155- [56] Referenes Clted UNITED STATES PATENTS 3,249,109 5/1966 Maeth et a1 128/268 3,328,259 6/1967 Anderson 128/156 X 3,339,546 9/1967 Chen 128/156 3,444,858 5/1969 Russell 128/268 X 3,464,413 9/1969 Goldfarb et al.... 128/268 3,520,949 7/1970 Shepherd et al 128/156 UX Primary Examiner-Charles F. Rosenbaum Attorney-Steven D. Goldby PATENTEUAUGIOBII 3,59 ,123

INVENTOR Alejandro Zaffaroni WSW BANDAGE FOR ADMINISTERING DRUGS BACKGROUND OF THE INVENTION This invention relates to a bandage for use in the continuous administration of systemically active drugs.

One primary objective of drug therapy is to achieve a particular (uniform, variable, or modulated) blood level of drug in circulation for a period of time (hours, days, months). Many drugs, such as the steroidal hormones, are absorbed in a relatively short period of time, and are not long acting due to rapid metabolism and excretion following administration. To obtain the desired therapeutic effect, it is necessary in most cases to establish a dosage regime of multiple unit doses over a 24 hour period. Most drugs are administered orally or by injection and neither of these modes of administration achieves the desired blood level of drug in circulation in the typical case.

With oral administration of drugs, it is difficult if not impossible to achieve a constant blood level of drug in circulation. This is true even though the drug is administered at periodic intervals according to a well-defined schedule. One reason for this is that the rate of absorption of drugs through the gastrointestinal tract is affected by the contents of the tract. Such variables as whether the drug is administered before or after eating and the type and quantity of food eaten (for example, high or low fat content) or administered before or after a bowel movement, can control the rate of absorption of the drug in the gastrointestinal tract. As most of the absorption of drugs takes place in the small intestine, the time of passage through the small intestine is another governing factor. This in turn is affected by the rate of peristaltic contracting, adding further uncertainty. Also important is the rate of circulation of blood to the small intestine.

The almost inevitable result of oral administration of drugs through the gastrointestinal tract is that the level of drug in circulation surges to a high each time the drug is administered, followed by a decline in concentration in the blood and body compartments. Thus, a plot of drug in circulation following a dosage schedule of several tablets a day has the appearance of a series of peaks, which may surpass the toxic threshold, and valleys. Each time the blood level decreases below a critical point needed to achieve the desired therapeutic effect that effect will no longer be obtained. Worse still, with antimicrobial drugs, the disease-producing micro-organisms rapidly multiply when the concentration of drug in circulation descends below a critical point. It is likely that the drug-resistant mutant strains which are becoming increasingly prevalent and represent one of the major problems in the therapeutics of infectious diseases are formed precisely at such times.

One approach to this problem has been the advent of the socalled sustained release or time-capsule in oral dosage form. While many of these perform satisfactorily in vitro and in animal or clinical studies under controlled conditions of nutrition and activity, there is little or no evidence that these dosage forms are effective for achieving a continuous and predictable level of drug in circulation over a prolonged period of time under the normal conditions encountered by the outpatient.

Many effective therapeutic agents are destroyed by microbial flora of G.l. secretions or are poorly absorbed in the gastrointestinal tract.

Administration of drugs by injection is inconvenient, painful, and the risk of local tissue reaction and of infection is serious. Moreover, the typical result of administration by injection is a surge in blood level concentration of the drug immediately after injection, followed by a decline and another surge in concentration upon subsequent injections.

Other dosage forms such as rectal suppositories and sublingual lozenges also produce nonuniform levels of the therapeutic agent in circulation. These dosage forms require great patient cooperation, have low patient acceptability, and are sparingly used throughout most of the world.

Dosage forms described above all bring about a pulse entry of drug, that is, a concentrated dose of drug is brought into contact with an organ of entry at a particular time unit. Undoubtedly, this creates drug concentrations beyond the capacity of the active centers to accept (that is, the saturation point is exceeded by many orders of magnitude) and, also, until dilution in body fluids takes place, may exceed the capacity of metabolic and excretory mechanisms. The result is that a toxic level of drug is allowed to build, for a period of time, with detrimental effects for particular tissues or organs. To obtain persistence of effect, the usual industrial approach is to make the initial dose high or to modify the drug structure to obtain a longer metabolic half-life of the drug in circulation long. Raising the initial dosage only worsens the problem. Many derivatives with long half-lives have a lower therapeutic index (ratio between the median toxic dose and the median effective dose) than that of the parent compounds; and therefore these approaches are not the answer to the problem.

To avoid the problems discussed above, it has been suggested that systemically active drugs can be administered through the skin. Percutaneous administration can have the advantage of permitting continuous administration of drug to circulation over a prolonged period of time to obtain a uniform delivery rate and blood level of drug. Commencement and termination of drug therapy are initiated by the application and removal of the dosing device from the skin. Uncertainties of administration through the gastrointestinal tract and the inconvenience of administration by injection are eliminated. Since a high concentration of drug never enters the body, problems of pulse entry are overcome and metabolic half-life is not a factor of controlling importance.

Despite these advantages of administering systemically active drugs through the skin, prior devices designed for this purpose were either impractical or inoperative and did not provide continuous administration and delivery rate. This form of administration has not been accepted by the medical profession and the only prior art manner of obtaining continuous delivery rate remains the continuous intravenous drip.

SUMMARY OF THE INVENTION Accordingly, an object of this invention is to provide a device for the administration of systemically active drugs which overcomes the aforesaid disadvantages inherent in prior art modes of administration.

Another object of this invention is to provide a reliable and easily applied device for continuously administering controlled quantities of systemically active drugs through the skin.

Still another object of this invention is to provide a device for administering systemically active drugs through the oral mucosa.

A further object of this invention is to provide a complete dosage regime for a particular time period, the use of which requires patient intervention only for initiation and termination.

In accomplishing these objects, one feature of this invention resides in a bandage for use in the continuous administration of systemically active drugs by absorption. The bandage is comprised of a backing member bearing a pressure-sensitive adhesive layer on one surface thereof. The pressure-sensitive adhesive has distributed therethrough microcapsules acting as an external drug reservoir and comprising a systemically active drug encapsulated with a material permeable to passage of the drug. The drug is in a form suitable for absorption through the skin or oral mucosa.

Other objects, features, and advantages of the invention will be apparent to those skilled in the art from the detailed description of the invention which follows, and from the drawings.

BRIEF DESCRIPTION OF DRAWINGS In the drawings:

FIG. 1 is a perspective view of the bandage of the invention and FIG. 2 is a cross-sectional view of the bandage of the invention.

As illustrated in FIGS. 1 and 2, the bandage of this invention is comprised of a backing member 11 bearing a pressuresensitive adhesive layer 12 on one surface thereof. Adhesive layer 12 has microcapsules 13 of a systemically active drug encapsulated with a material permeable to passage of the drug uniformly distributed therethrough.

DETAILED DESCRIPTION OF THE INVENTION To use the bandage 10 of the invention, it is applied to the patient's skin. Adhesive layer 12 should be in firm contact with the skin, forming a tight seal therewith. Drug within microcapsules 13, whether in solid form or solution, migrates through the walls of the microcapsules, acting as a solubility membrane, and into adhesive layer 12, as by diffusion. Ordinarily, one would expect the drug migration to cease when sufficient drug has reached the outer surface of microcapsules 13 to create an equilibrium or when adhesive layer 12 has become saturated with the drug. However, when adhesive layer 12 is in contact with the patients skin, drug molecules which are continuously removed from the outer surface of microcapsules l3 migrate through the adhesive to the outer surface of the adhesive layer and are absorbed by the skin. Absorbed drug molecules pass through the skin and enter circulation through the capillary network. While the bandage may be applied to any area of the patients skin, the lower back and buttocks are the areas of choice. In like manner, the bandage can be applied to the mucosa of the mouth, for example, by application to the palate or the buccal mucosa, to obtain absorption of the drug by the oral mucosa. Although obtaining a liquidtight adhesive seal between the skin and bandage is important, it becomes critical in the mouth. Without such a seal, irrigation of the oral mucosa by saliva will transfer the drug to the gastrointestinal tract, rather than to circulation through the oral mucosa.

Those skilled in the art will appreciate that the bandage of this invention significantly differs from prior art wound dressings or bandages containing antiseptics or topically active drugs. The bandage of this invention contains an encapsulated systemically active drug and is applied to unbroken skin, to introduce the drug to circulation in the bloodstream and produce a pharmacologic response at a site remote from the point of application of the bandage. Thus, the bandage functions as an external drug reservoir and provides a complete dosage regime for a particular time period.

In practicing this invention, one can employ any systemically active drug which will be absorbed by the body surface to which the bandage is applied. The term systemically active drug" is used herein in its broadest sense as indicating a substance or composition which will give a pharmacologic response at a site remote from the point of application of the bandage. Of course, the amount of drug necessary to obtain the desired therapeutic effect will vary depending on the particular drug used. Suitable drugs include, without limitation, antimicrobial agents such as penicillin, tetracycline, oxytetracycline, chlortetracycline, chloramphenicol, and sulfonamides; sedatives and hypnotics such as pentabarbital' sodium, phenobarbital, secobarbital sodium, codeine, (a-bromoisovaleryl) urea, carbromal, and sodium phenobarbital; psychic energizers such as 3( Z-aminopropyl) indole acetate and 3-)2-aminobutyl) indole acetate; tranquilizers such as reserpine, chlorpromazine hydrochloride, and thiopropazate hydrochloride; hormones such as adrenocorticosteroids, for example, tia-methylprednisolone, cortisone, cortisol, and triamcinolone; androgenic steroids, for example, methyltestosterone, and fluoxymesterone; estrogenic steroids, for example, estrone, l7B-estrodiol and ethinyl estradiol; progrestational steroids, for example, l7a-hydronyprogesterone acetate, medroxyprogesterone acetate, l9-norprogesterone, and norethindrone; and thyroxine; antipyretics such as aspirin, salicylamide, and sodium salicylatc; antispasmodics such as atropine, mcthscopolaminc bromide, methscopolamine bromide with phenobarbital; antimalarials such as the 4- aminoquinolines, S-aminoguinolines, and pyrimethamine; and nutritional agents such as vitamins, essential amino acids, and essential fats.

Drugs which alone do not pass through the skin or oral mucosa can be dissolved in an absorbable, pharmacologically acceptable solvent to achieve passage through the external body layer. Suitable solvents include alcohols containing 2 to 10 carbon atoms, such as hexanol, cyclohexanol, benzylalcohol, l,2-butanediol, glycerol, and amyl alcohol; hydrocarbons having 5 to 12 carbon atoms such as n-hexane, cyclohexane, and ethyl benzene; aldehydes and ketones having 4 to 10 carbon atoms such as heptyl aldehyde, cyclohexanone, and benzaldehyde; esters having 4 to 10 carbon atoms such as amyl acetate and benzyl propionate; ethereal oils such as oil of eucalyptus, oil of rue, cumin oil, limonene, thymol, and lpinene; halogenated hydrocarbons having two to eight carbon atoms such as n-hyxyl chloride, n-hyxyl bromide, and cyclohexyl chlorides; or mixtures of any of the foregoing solvents. Also, with drugs which do not pass through the skin or oral mucosa, simple pharmacologically acceptable derivatives of the drugs, such as ethers, esters, amides, acetals, etc. having the desired absorption property can be prepared and used in practicing the invention. Of course, the derivatives should be such as to convert to the active drugs within the body through the action of body enzyme assisted transformations, PH, etc.

Materials used to encapsulate the drug or drug solution and form the microcapsules to be distributed throughout the adhesive must be permeable to the drug to permit passage of the drug, as by difiusion, through the walls of the microcapsules at a relatively low rate. Normally, the rate of passage of the drug through the walls of the microcapsules is dependent on the solubility of the drug or drug solution therein, as well as on the microcapsule wall thickness. This means that selection of appropriate encapsulating materials will be dependent on the particular drug used in the bandage. By varying the encapsulating material and the wall thickness, the dosage rate per area of bandage can be controlled.

One presently preferred class of encapsulating materials are the organopolysiloxane rubbers, commonly known as silicone rubbers. Suitable silicone rubbers are the conventional heatcurable silicone rubbers and the room-temperature-vulcanizable silicone rubbers.

Conventional silicone rubbers which are converted to the rubbery state by the action of heat are predominantly linear organopolysiloxanes having an average degree of substitution of about two organic groups attached directly to silicon per silicon atom. Preferably, the organic groups are monovalent hydrocarbon radicals such as alkyl, aryl, alkenyl, alkaryl, aralkyl, and of these, the methyl, phenyl and vinyl radicals are most preferred.

Variation of the organic groups in the silicone rubber can be used to vary the solubility of the drug in the polymer and hence can control the speed of the migration of the drug through the polymer. Also, drugs which are insoluble in one type of silicone rubber may be soluble in a different type of polymer. One especially preferred class of silicone polymers are the pure dimethylpolysiloxanes.

Room-temperature-vulcanizable silicone rubbers are also commercially available and are known to the art. In general, they employ the same silicone polymers as discussed above although the polymers often contain a greater amount of silicon-bonded hydroxy groups. This type of silicone rubber will cure at room temperature in the presence of an appropriate catalyst, such as stannous 2-ethylhexoate.

Exemplary patents disclosing the preparation of silicone rubbers are U.S. Pat. Nos. 2,54l,l37, 2,723,966, 2,863,846, 2,890,188, 2,927,907, 3,002,951, and 3,035,016.

Another class of materials suitable for encapsulating drugs are the hydrophilic polymers of monoesters of an olefinic acid, such as acrylic acid and mcthacrylic acid. Exemplary polymers of this class include poly (hydroxyethylacrylatc) and poly (hydronyethylmethacrylatc). These polymers are commercially available and their preparation is described in U.S. Pat. Nos. 2,976,576 and 3,220,960, as well as in Belgian Pat. No. 701,813. When using these hydrophilic polymers, the drug is normally dissolved in a solvent such as a lower alcohol to promote passage of the drug through the polymer.

Other exemplary materials for use as encapsulating media in this invention include polyvinylalcohol, polyvinylacetate, plasticized polyvinylchloride, plasticized nylon, collagen, modified collagen, gelatin, and waxes such as polyethylene wax, oxidized polyethylene wax, hydrogenated castor oil, etc.

To provide the microcapsules, the encapsulating materials can be uniformly impregnated with the drug or drug solution to form microcapsules which are a matrix having the drug distributed therethrough. Alternatively, particles or solutions of drugs can be encapsulated with thin coatings of the encapsulating material to form microcapsules having an interior chamber containing the drug. If desired, particles of a matrix, such as starch, gum acacia, gum tragacanth, and polyvinylchloride, can be impregnated with the drug and encapsulated with another material such as the encapsulating materials previously discussed which function as a solubility membrane to meter the flow of drug to the adhesives; use of a matrix and a different solubility membrane can slow the passage of the drug from the microcapsules which is desirable with drugs that are released too rapidly from available encapsulating materials. In contrast, by encapsulating a solution of the drug, the solvent speeds passage of the drug through the microcapsule walls.

Any of the encapsulation or impregnation techniques known in the art can be used to prepare the microcapsules to be incorporated into the adhesive base in accord with this invention. Thus, the drug or drug solution can be added to the encapsulating material in liquid form and uniformly distributed therethrough by mixing; or solid encapsulating material can be impregnated with the drug by immersion in a bath of the drug to cause the drug to diffuse into the material. Subsequently, the solid material can be reduced to fine microcapsules by grinding, each of the microcapsules comprising drug coated with and distributed throughout the encapsulating material. Alternatively, fine particles or solutions of the drug can be encapsulated with a coating. One suitable technique comprises suspending dry particles of the drug in an airstream and contacting that stream with a stream containing the encapsulating material to coat the drug particles. Usually, the microcapsules have an average particle size of from 1 to 1,000 microns, although this is not critical to the invention.

The microcapsules, however made, are then mixed with a pressure-sensitive adhesive. Any of the well-known dermatologically acceptable pressure-sensitive adhesives which permit drug migration can be used in practicing this invention. Exemplary adhesives include acrylic resins such as polymers of esters of acrylic acid with alcohols such as n-butanol, n-pentanol, isopentanol, Z-methyl butanol, l-methyl butanol, l-methyl pentanol, 2-methyl pentanol, 3-methyl pentanol, 2-ethyl butanol, isooctanol, n-deconal, or n-dodecanol, alone or copolymerized with ethylenically unsaturated monomers such as acrylic acid, methacrylic acid, acrylamide, methacrylamide, N-alkoxymethyl acrylamides, N-alkoxymethyl methacrylamides, N-tert. butylacrylamide, itaconic acid, vinylacetate, N-branched alkyl maleamic acids wherein the alkyl group has to 24 carbon atoms, glycol diacrylates. or mixtures of these; elastomeric silicone polymers; polyurethane elastomers; rubbery polymers, such as polyisobutylene, polyisoprene, and polybutadiene; vinyl polymers, such as polyvinylalcohol, polyvinyl pyrrolidone, and polyvinylacetate; cellulose derivatives such as ethyl cellulose, methyl cellulose, and carboxymethyl cellulose; natural gums such as guar, acacia, pectins, etc. For use in contact with the oral mucosa rubbery. polymers, such as polyisobutylene, with or without gum modifiers gives good results, as do polyvinyl alcohol, polyvinyl pyrrolidone, cellulose derivatives and others. The adhesive-s may be compounded with tackifiers and stabilizers as is well known in the art.

The mixture of microcapsules and pressure-sensitive adhesive is then coated onto a backing member, usually to provide an adhesive layer 0.01 to 7 millimeters thick, although these limits can be exceeded if more or less drug is required. The purpose of the backing is to provide support for the bandage and to prevent passage of the drug through the adhesive surface away from the body surface to which the bandage is applied. Backing members can be flexible or nonflexible and suitable materials include cellophane, cellulose acetate, ethyl cellulose, plasticized vinyl acetate-vinyl chloride copolymers, polyethylene terephthalate, nylon, polyethylene, polyvinylidene chloride, coated flexible fibrous backings such as paper and cloth, and aluminum foil.

The required surface area of the bandage will depend on the activity of the drug and the rate of its absorption through the skin. Usually, the adhesive face of the bandage has a surface area of 0.5 to 400 square centimeters, although smaller or larger bandages can be used.

It will be appreciated that on encapsulating the drug with a material, such as silicone rubber, the drug immediately begins to migrate into and through the encapsulating material. On mixing the microcapsules with the adhesive the drug passing through the walls of the microcapsules will enter the adhesive, eventually saturating the adhesive with the drug. To prevent passage of the drug away from the exposed surface of the adhesive prior to use, the adhesive surface of the bandage generally is covered with a protective release film or foil, such as waxed paper, prior to use. Alternatively, the exposed rear surface of the backing member can be coated with a low-adhesion backsize and the bandage rolled about itself.

The following examples will serve to illustrate the invention without in any way being limiting thereon.

EXAMPLE I 2-hydroxyethyl methacrylate grams) is mixed with tertiary butyl peroctoate (0.20 gram). Ethylene glycol dimethacrylate (0.20 gram) is added along with 4 grams of sodium bicarbonate as a foaming agent. The mixture is heated to 70 C. and the resulting solid, firable polymeric foam is ground into fine powder of 20-micron average particle size. The polymeric powder (10 grams) is mixed with chloramphenicol antibiotic (2 grams) dissolved in ethyl alcohol and the resultant mixture placed on a mechanical roller until the polymeric powder has absorbed the antibiotic. The solution is then filtered.

The resulting microcapsules of chloramphenical antibiotic are mixed with 100 grams of a 22 percent solution in heptaneisopropylalcohol (70:30) of a rubbery copolymer of isooctyl acrylate and acrylic acid (94:6) adhesive to uniformly distribute the microcapsules through the adhesive solution. The resulting slurry is coated onto a cellophane sheet l0 centimeters in width by 10 centimeters in length and the solvent removed by evaporation.

When applied to the skin of a subject, the resulting bandage is effective to administer chloramphenicol antibiotic through the skin to circulation to provide a continuous administration of the daily dose of the antibiotic.

EXAMPLE ll Liquid dimethyl silicone rubber (100 grams, Dow-coming Silastic) is mixed with finely divided crystalline megesterol acetate (5 grams). After uniformly mixing the hormone with the unvulcanized silicone rubber, 0.5 gram of stannous octoate catalyst is added and the rubber cured at room temperature. The resulting silicone rubber body is reduced to an average particle size of 100 microns.

5 grams of the resulting encapsulated megesterol acetate are mixed with an elastomeric silicone pressure-sensitive adhesive 10 grams) to uniformly distribute the microcapsules throughout the adhesive. Immediately thereafter, the adhesive mixture is coated onto one surface of a IOO-square centimeter. Mylar sheet. The resulting bandage is used for fertility regulation.

Thus, this invention provides an easy to use device for administering systemically active drugs through the skin and oral mucosa. Uncertainties of administration through the gastrointestinal tract are avoided and a constant level of drug in circulation can be obtained. Treatment is begun by applying the bandage to the skin or oral mucosa and terminated by removing it therefrom. The bandage can contain and administer the complete dosage requirements for a particular time period, for example, for 24 hours. Intervention by the patient is required only to apply and remove the bandage, so that uncertainties are eliminated.

While there have been shown and described and pointed out the fundamental novel features of the invention as applied to the preferred embodiment, it will be understood that various omissions and substitutions and changes in the form and details of the bandage illustrated may be made by those skilled in the art without departing from the spirit of the invention. It is the intention, therefore, to be limited only as indicated by the scope of the following claims.

What I claim is:

1. A medical bandage for use in the continuous administration to circulation of controlled quantities of systemically active drugs over a prolonged period of time by absorption through the external body skin or mucosa, said bandage comprising (l) a backing member bearing (2) a pressure-sensitive adhesive on one surface thereof, said pressure-sensitive adhesive having distributed therethrough (3) a plurality of discrete microcapsules, each of which microcapsules comprising a systemically active drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of drug from the said microcapsules to the skin or mucosa at a controlled and predetermined rate over a prolonged period of time.

2. The bandage as defined by claim 1, wherein each of said microcapsules (3) is comprised of systemically active drug formulation microencapsulated with the said drug release rate controlling wall material.

3. The bandage as defined by claim 1, wherein each of said microcapsules (3) is comprised of a matrix of the drug release rate controlling wall material, said matrix having the systemically active drug formulation distributed therethrough.

4. The bandage as defined by claim 1, wherein the systemically active drug formulation is soluble in the drug release rate controlling material.

5. The bandage as defined by claim 1, wherein the pressuresensitive adhesive is permeable to passage of the systemically active drug formulation.

6. The bandage as defined by claim I, wherein the drug formulation comprises a pharrnacologically acceptable solvent.

7. The bandage as defined by claim 1, wherein said drug release rate controlling material is silicone rubber.

8. The bandage as defined by claim 1, wherein said drug release rate controlling material is a hydrophilic polymer of an ester of an olefinic acid.

9. The bandage as defined by claim 1, wherein the pressuresensitive adhesive is adapted to provide a liquidtight adhesive seal between the skin or mucosa and the bandage.

10. The bandage as defined by claim 1, wherein the surface of a pressure-sensitive adhesive 3) is covered with a protective release coating (4).

11. The bandage as defined by claim 1, wherein the outer surface of the backing member l) is coated with a low adhesion backsize (5).

12. The bandage as defined by claim 1, wherein said microcapsules have an average particle size of from 1 to 1,000 microns.

13. The bandage as defined by claim 1, wherein the adhesive face of the bandage has an area of 0.5 to 400 square centimeters.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3249109 *Nov 1, 1963May 3, 1966Maeth HarryTopical dressing
US3328259 *Jan 8, 1964Jun 27, 1967Parachem CorpDressing for a wound containing a hemostatic agent and method of treating a wound
US3339546 *Dec 13, 1963Sep 5, 1967Squibb & Sons IncBandage for adhering to moist surfaces
US3444858 *May 11, 1966May 20, 1969Higham S RussellMethod and means for administering drugs
US3464413 *May 26, 1967Sep 2, 1969United Merchants & MfgMedical bandages
US3520949 *Jul 26, 1966Jul 21, 1970Nat Patent Dev CorpHydrophilic polymers,articles and methods of making same
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3731683 *Jun 4, 1971May 8, 1973Alza CorpBandage for the controlled metering of topical drugs to the skin
US3797494 *Aug 9, 1971Mar 19, 1974Alza CorpBandage for the administration of drug by controlled metering through microporous materials
US3828777 *Nov 8, 1971Aug 13, 1974Alza CorpMicroporous ocular device
US3901232 *Oct 26, 1973Aug 26, 1975Alza CorpIntegrated device for administering beneficial drug at programmed rate
US3911099 *Jan 23, 1974Oct 7, 1975Defoney Brenman Mayes & BaronLong-acting articles for oral delivery and process
US3921636 *Apr 22, 1974Nov 25, 1975Alza CorpNovel drug delivery device
US3951622 *Dec 4, 1974Apr 20, 1976Wilk Immanuel JTime release perfume method and device
US3960150 *Sep 15, 1975Jun 1, 1976Alza CorporationBioerodible ocular device
US3961628 *Apr 21, 1975Jun 8, 1976Alza CorporationOcular drug dispensing system
US3972995 *Apr 14, 1975Aug 3, 1976American Home Products CorporationDosage form
US3981303 *Jul 31, 1975Sep 21, 1976Alza CorporationBioerodible ocular device
US3986510 *Aug 1, 1975Oct 19, 1976Alza CorporationBioerodible ocular device
US3993071 *Jul 24, 1975Nov 23, 1976Alza CorporationBioerodible ocular device
US3993073 *Mar 3, 1975Nov 23, 1976Alza CorporationNovel drug delivery device
US3996934 *Aug 9, 1971Dec 14, 1976Alza CorporationMedical bandage
US4026290 *Nov 18, 1975May 31, 1977Fisons LimitedMethod of administering medicaments through the skin
US4031894 *Sep 7, 1976Jun 28, 1977Alza CorporationBandage for transdermally administering scopolamine to prevent nausea
US4039653 *Jul 21, 1975Aug 2, 1977Defoney, Brenman, Mayes & BaronBreath deodorants, sustained release
US4186743 *Feb 28, 1978Feb 5, 1980Personal Products CompanyPerfuming self-adhering napkins
US4210633 *Oct 20, 1978Jul 1, 1980Eli Lilly And CompanyFlurandrenolide film formulation
US4291014 *Jul 11, 1980Sep 22, 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing estradiol diacetate
US4291015 *Jun 26, 1980Sep 22, 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing a vasodilator
US4292301 *Jul 9, 1980Sep 29, 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing ephedrine
US4292302 *Jul 9, 1980Sep 29, 1981Key Pharmaceuticals, Inc.Comprising plasticized polyvinyl alcohol and polyvinylpyrrolidone; bandages; sustained release
US4292303 *Jul 9, 1980Sep 29, 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing clonidine
US4294820 *Jul 9, 1980Oct 13, 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing phenylephrine
US4310509 *Jul 31, 1979Jan 12, 1982Minnesota Mining And Manufacturing CompanyPressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4321252 *Dec 17, 1980Mar 23, 1982Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing ester derivatives of estradiol
US4323557 *Jul 31, 1979Apr 6, 1982Minnesota Mining & Manufacturing CompanyPressure-sensitive adhesive containing iodine
US4329333 *Nov 24, 1980May 11, 1982Arthur BarrMethod for the oral treatment of dogs and other animals
US4336243 *May 4, 1981Jun 22, 1982G. D. Searle & Co.Transdermal nitroglycerin pad
US4340043 *Nov 15, 1979Jul 20, 1982Smith & Nephew Research Ltd.Adhesive-coated sheet material incorporating anti-bacterial substances
US4409206 *Aug 14, 1981Oct 11, 1983Boehringer Ingelheim GmbhPouring, acrylate, skins
US4455146 *Mar 2, 1982Jun 19, 1984Hisamitsu Pharmaceutical Co., Ltd.Novel plasters
US4460369 *Dec 21, 1981Jul 17, 1984Smith & Nephew Research Ltd.Adhesive-coated sheet material incorporating anti-bacterial substances
US4460562 *Mar 30, 1983Jul 17, 1984Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing propranolol
US4492685 *Jan 30, 1984Jan 8, 1985Key Pharmaceuticals, Inc.Portection of burned or wounded patients
US4563184 *Oct 17, 1983Jan 7, 1986Bernard KorolSynthetic resin wound dressing and method of treatment using same
US4564010 *Apr 18, 1984Jan 14, 1986Daubert Coated Products Inc.Pressure sensitive adhesive film for medical use
US4568343 *Oct 9, 1984Feb 4, 1986Alza CorporationSkin permeation enhancer compositions
US4597961 *Jan 23, 1985Jul 1, 1986Etscorn Frank TTranscutaneous application of nicotine
US4614787 *Nov 13, 1984Sep 30, 1986Thermedics, Inc.Drug dispensing wound dressing
US4631227 *Dec 5, 1983Dec 23, 1986Kenji NakamuraToilet article
US4638043 *Aug 23, 1985Jan 20, 1987Thermedics, Inc.Drug release system
US4666441 *Dec 17, 1985May 19, 1987Ciba-Geigy CorporationMulticompartmentalized transdermal patches
US4667032 *Oct 10, 1985May 19, 1987Merck Frosst Canada, Inc.Leukotriene biosynthesis inhibitors, antiallergens, antiinflammatory agents
US4690683 *Jul 2, 1985Sep 1, 1987Rutgers, The State University Of New JerseyTransdermal varapamil delivery device
US4719226 *Dec 31, 1984Jan 12, 1988Nitto Electric Industrial Co., Ltd.Sustained drug release
US4727868 *May 20, 1987Mar 1, 1988Thermedics, Inc.Anisotropic wound dressing
US4738848 *Jun 4, 1986Apr 19, 1988Nitto Electric Industrial Co., Ltd.Anti-inflammatory analgesic adhesive preparation
US4743249 *Jun 10, 1987May 10, 1988Ciba-Geigy Corp.Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4746515 *Feb 26, 1987May 24, 1988Alza CorporationSkin permeation enhancer compositions using glycerol monolaurate
US4751133 *May 11, 1987Jun 14, 1988Thermedics, Inc.Medical patches and processes for producing same
US4755384 *Mar 15, 1984Jul 5, 1988Kozponti Valto- es Hitelbank RT, Innovacious AlapExternally applied antispasmatic products
US4764362 *Oct 22, 1986Aug 16, 1988The Cook Bates CompanyNail-conditioning emery boards and process for making them
US4764379 *Aug 24, 1987Aug 16, 1988Alza CorporationTransdermal drug delivery device with dual permeation enhancers
US4777046 *Oct 1, 1985Oct 11, 1988Nippon Kayaku Kabushiki KaishaSustained release drug delivery for oral administration
US4781924 *Nov 9, 1987Nov 1, 1988Alza CorporationRelease by moisture activator
US4788062 *Feb 26, 1987Nov 29, 1988Alza CorporationDispersion in polymer matrix, permeation promoter
US4812305 *Nov 9, 1987Mar 14, 1989Vocal Rodolfo SWell medicine strip
US4813976 *Apr 7, 1988Mar 21, 1989The Cook Bates CompanyNail-conditioning emery boards and process for making them
US4816258 *Feb 26, 1987Mar 28, 1989Alza CorporationDrug delivery, ethylneestradiol, leyonorgestrel
US4820720 *Mar 29, 1988Apr 11, 1989Alza CorporationGlycerol monolaurate and ethanol enhancers;controlled drug delivery
US4834979 *Dec 14, 1987May 30, 1989Alza CorporationMedical bandage for administering beneficial drug
US4837027 *Aug 9, 1988Jun 6, 1989Alza CorporationTherapeutic agent stored as salt, moisture activates
US4839174 *Oct 5, 1987Jun 13, 1989Pharmetrix CorporationNovel transdermal nicotine patch
US4859667 *Jan 14, 1987Aug 22, 1989Merck Frosst Canada, Inc.Pharmaceutical compositions of phenothiazone derivatives and analogs
US4863738 *Nov 23, 1987Sep 5, 1989Alza CorporationTransdermal drug delivery
US4865848 *Feb 26, 1987Sep 12, 1989Alza CorporationSkin permeation enhancer compositions using sucrose esters
US4879275 *May 27, 1988Nov 7, 1989Nelson Research & Development Co.Penetration enhancers for transdermal delivery of systemic agent
US4880690 *Sep 9, 1988Nov 14, 1989Thermedics, Inc.Perfume patch
US4885154 *Mar 1, 1988Dec 5, 1989Alza CorporationCoadministering a metabolic modulator
US4906475 *Feb 16, 1988Mar 6, 1990Paco Pharmaceutical ServicesEstradiol transdermal delivery system
US4908027 *Sep 12, 1986Mar 13, 1990Alza CorporationSubsaturated transdermal therapeutic system having improved release characteristics
US4917688 *Jun 27, 1988Apr 17, 1990Nelson Research & Development Co.Bandage for transdermal delivery of systemically-active drug
US4917895 *Jul 14, 1988Apr 17, 1990Alza CorporationTransdermal drug delivery device
US4920101 *Sep 30, 1987Apr 24, 1990Nelson Research & Development Co.For enhancing penetration of physiologically active agents through skin or other membranes
US4940586 *Oct 13, 1988Jul 10, 1990Alza CorporationSkin permeation enhancer compositions using sucrose esters
US4943435 *Oct 28, 1988Jul 24, 1990Pharmetrix CorporationTransdermal drug delivery, polyethylene membrane
US4956171 *Jul 21, 1989Sep 11, 1990Paco Pharmaceutical Services, Inc.Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US4959208 *Oct 28, 1988Sep 25, 1990Ppg Industries, Inc.Active agent delivery device
US4969871 *Feb 15, 1989Nov 13, 1990Alza CorporationIntravenous system for delivering a beneficial agent
US4973468 *Mar 22, 1989Nov 27, 1990Cygnus Research CorporationSkin permeation enhancer compositions
US4985016 *Feb 15, 1989Jan 15, 1991Alza CorporationIntravenous system for delivering a beneficial agent
US5000956 *Jul 8, 1988Mar 19, 1991Alza CorporationPrevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US5004610 *Jun 14, 1990Apr 2, 1991Alza CorporationSubsaturated nicotine transdermal therapeutic system
US5026556 *Nov 10, 1988Jun 25, 1991Norwich Eaton Pharmaceuticals, Inc.Buprenorphine in carrier comprises lower alkyl diols or triols and a polar lipid
US5034386 *Aug 17, 1988Jul 23, 1991Whitby Research, Inc.Fungicides
US5035886 *May 10, 1990Jul 30, 1991Ppg Industries, Inc.Active agent delivery device
US5045059 *Aug 15, 1990Sep 3, 1991Alza CorporationIntravenous system for delivering a beneficial agent
US5049387 *Jun 9, 1989Sep 17, 1991Alza CorporationInducing skin tolerance to a sensitizing drug
US5053227 *Jun 12, 1990Oct 1, 1991Cygnus Therapeutic SystemsTransmittance of drug in mixture of diethylene glycol ethyl and/or methyl ether and ester
US5059189 *Sep 8, 1987Oct 22, 1991E. R. Squibb & Sons, Inc.Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US5059426 *Jun 12, 1990Oct 22, 1991Cygnus Therapeutic SystemsSkin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5061106 *Nov 6, 1989Oct 29, 1991Colgate-Palmolive CompanyToothbrush with slow release of disinfectant and antibacterial agents and method of manufacturing the same
US5068226 *Apr 30, 1990Nov 26, 1991Cyclex, Inc.Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5071645 *Mar 20, 1991Dec 10, 1991Ppg Industries, Inc.Process of producing an active agent delivery device
US5071657 *Aug 31, 1990Dec 10, 1991Schering AktiengesellschaftDevice for transdermal administration of active medicinal agents
US5077054 *Nov 27, 1990Dec 31, 1991Alza CorporationPrevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US5104899 *Aug 13, 1990Apr 14, 1992Sepracor, Inc.Methods and compositions for treating depression using optically pure fluoxetine
US5118509 *Aug 30, 1991Jun 2, 1992Alza CorporationInducing skin tolerance to a sensitizing drug
US5120545 *Aug 3, 1990Jun 9, 1992Alza CorporationSensitizing drug and antigen processing-inhibiting agent
US5124157 *Aug 18, 1989Jun 23, 1992Cygnus Therapeutic SystemsUsing adhesive skin patch
US5130139 *Jul 6, 1990Jul 14, 1992Alza CorporationCoadministering lysosomac uptake inhibiting agent
US5133970 *Jul 11, 1990Jul 28, 1992Rohm Gmbh Chemische FabrikWater-soluble pressure-sensitive skin-adhesive and use thereof
US5149539 *Nov 15, 1991Sep 22, 1992Alza CorporationReduction or prevention of sensitization to drugs
US5160320 *Feb 14, 1990Nov 3, 1992Alza CorporationIntravenous system for delivering a beneficial agent
US5160741 *Nov 13, 1991Nov 3, 1992Alza CorporationReduction or prevention of skin irritation by drugs
US5171576 *Aug 30, 1991Dec 15, 1992Alza CorporationPrevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US5173302 *Sep 28, 1990Dec 22, 1992Medtronic, Inc.2-acrylamido-2-methyl propanesulfonic acid copolymer, ethylene /propylene oxide derivative humectant, crosslinking monomer, initiator
US5189986 *Sep 23, 1991Mar 2, 1993Alza CorporationVeterinary transdermal active agent delivery device
US5198223 *Mar 9, 1992Mar 30, 1993Alza CorporationEstrogen/Progesterone, Skin Permeation Enhancer
US5203768 *Jul 24, 1991Apr 20, 1993Alza CorporationTransdermal delivery device
US5204339 *Aug 6, 1990Apr 20, 1993Whitby Research, Inc.Penetration enhancers for transdermal delivery of systemic agents
US5217718 *Sep 17, 1991Jun 8, 1993Cygnus Therapeutic SystemsUsing pressure sensitive adhesive skin patch
US5223261 *Dec 31, 1991Jun 29, 1993Riker Laboratories, Inc.Transdermal estradiol delivery system
US5225199 *Apr 23, 1991Jul 6, 1993Teijin LimitedMultilayer bandages of polyester films and adhesives
US5234690 *Aug 23, 1991Aug 10, 1993Cygnus Therapeutic SystemsTransdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5250028 *Aug 9, 1991Oct 5, 1993Alza CorporationIntravenous system for delivering a beneficial agent using permeability enhancers
US5268179 *Feb 14, 1992Dec 7, 1993Ciba-Geigy CorporationUltrasonically sealed transdermal drug delivery systems
US5273755 *Aug 23, 1991Dec 28, 1993Cygnus Therapeutic SystemsTransdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5273756 *Aug 23, 1991Dec 28, 1993Cygnus Therapeutic SystemsA backing, a pressure-rupturable reservoir, adsorbent wick, drug-permeable polymer adhesive, an unplasticized microporous membrane, and a drug-permeable membrane
US5284660 *Aug 21, 1992Feb 8, 1994Alza CorporationDelayed onset transdermal delivery device
US5286491 *May 18, 1992Feb 15, 1994Alza CorporationAdministering over a predetermined period of time
US5304379 *Nov 3, 1992Apr 19, 1994Alza CorporationA reservoir consists of tetracaine and metabolic modulator to inhibit monoamine oxidase enzyme
US5314694 *Mar 26, 1993May 24, 1994Alza CorporationTransdermal formulations, methods and devices
US5320850 *Feb 12, 1993Jun 14, 1994Alza CorporationTransdermal delivery of the gestogen ST-1435 and devices therefor
US5342623 *Jun 18, 1993Aug 30, 1994Alza CorporationSubsaturated transdermal therapeutic system having improved release characteristics
US5364634 *Nov 8, 1991Nov 15, 1994Southwest Research InstituteMouths; drug delivery
US5376377 *Dec 17, 1992Dec 27, 1994Alza CorporationTransdermal contraceptive formulations, methods and devices
US5378730 *Dec 3, 1992Jan 3, 1995Alza CorporationPermeation enhancer comprising ethanol and monoglycerides
US5402777 *Jun 3, 1992Apr 4, 1995Alza CorporationMethods and devices for facilitated non-invasive oxygen monitoring
US5410054 *Jul 20, 1993Apr 25, 1995Merck Frosst Canada, Inc.Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5411740 *Feb 8, 1994May 2, 1995Alza CorporationTransdermal administration of oxybutynin
US5422118 *Sep 21, 1992Jun 6, 1995Pure Pac, Inc.Transdermal administration of amines with minimal irritation and high transdermal flux rate
US5451407 *Jun 21, 1993Sep 19, 1995Alza CorporationReduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
US5464387 *Oct 27, 1994Nov 7, 1995Alza CorporationTransdermal delivery device
US5500222 *Feb 15, 1995Mar 19, 1996Alza CorporationMixed with monoglyceride permeation enhancer
US5508038 *Apr 16, 1990Apr 16, 1996Alza CorporationDrug delivery patches having mixture of high and low molecular weight polymers as adhesives which dissolve active agents, free of plasticizers and tackifiers
US5508039 *Oct 16, 1992Apr 16, 1996Alza CorporationControlled transdermal administration of melatonin
US5512292 *Dec 21, 1994Apr 30, 1996Alza CorporationTransdermal contraceptive formulations methods and devices
US5589511 *Apr 15, 1994Dec 31, 1996Sepracor Inc.Method for treating migraine headaches using optically pure S(+) fluoxetine
US5633008 *Aug 12, 1993May 27, 1997Osborne; James L.Method of administering nicotine transdermally
US5633009 *Nov 12, 1993May 27, 1997Sano CorporationTransdermal administration of azapirones
US5641504 *May 20, 1992Jun 24, 1997Alza CorporationTransdermal drug delivery
US5648396 *Jun 7, 1995Jul 15, 1997Sepracor Inc.Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
US5662928 *Apr 21, 1995Sep 2, 1997Ciba-Geigy CorporationMethod for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
US5691377 *Jul 14, 1994Nov 25, 1997University Of Maryland Eastern Shore And University Of Maryland College ParkUse of N-methyl-aspartic acid for enhancing growth and altering body composition
US5700478 *Aug 19, 1994Dec 23, 1997Cygnus, Inc.Comprising water soluble polymer and miscible water soluble plasticizer having specified properties
US5707663 *May 16, 1995Jan 13, 1998Alza CorporationSustained antiepileptic therapy
US5708035 *May 22, 1995Jan 13, 1998Sepracor Inc.Methods of use and compositions of R(-) fluoxetine
US5733255 *Oct 15, 1996Mar 31, 1998Novartis Finance CorporationThermopile powered transdermal drug delivery device
US5747065 *Sep 29, 1994May 5, 1998Lee; Eun SooMonoglyceride/lactate ester permeation enhancer for oxybutynin
US5750137 *Sep 29, 1994May 12, 1998Taskovich; Lina TormenDrug delivery, permeability, glycerides and lactates
US5785991 *Jun 7, 1995Jul 28, 1998Alza CorporationTransdermal drug delivery
US5817331 *Jun 7, 1995Oct 6, 1998Sano CorporationAbsorption; drug delivery device
US5820876 *Jun 6, 1995Oct 13, 1998Lts Lohmann Therapie-Systeme Gmbh & Co. KgButadiene-acrylonitrile-methyl acrylate terpolymer, paper, and aluminum sealing bag containing a nicotine patch
US5837280 *Jun 7, 1995Nov 17, 1998Sano CorporationTransdermal administration of azapirones
US5840327 *Aug 15, 1996Nov 24, 1998Alza CorporationTransdermal drug delivery device having enhanced adhesion
US5843468 *May 13, 1996Dec 1, 1998Alza CorporationSkin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5882675 *Mar 7, 1997Mar 16, 1999Nitto Denko CorporationPercutaneous absorption preparation
US5882676 *May 26, 1995Mar 16, 1999Alza CorporationSkin permeation enhancer compositions using acyl lactylates
US5891868 *Nov 21, 1997Apr 6, 1999Kaiser Foundation Health Plan, Inc.Methods for treating postmenopausal women using ultra-low doses of estrogen
US5900250 *Apr 30, 1998May 4, 1999Alza CorporationMonoglyceride/lactate ester permeation enhancer for oxybutnin
US5919478 *Jun 24, 1994Jul 6, 1999Alza CorporationIncorporating poly-N-vinyl amide in a transdermal system
US5939426 *Feb 28, 1997Aug 17, 1999Sepracor Inc.Also for motion sickness and vertigo
US5962464 *Jul 6, 1998Oct 5, 1999Sepracor Inc.Side effect reduction
US5980943 *Oct 21, 1997Nov 9, 1999Alza CorporationA time release dosage form comprising a semipermeable wall in contact with a therapeutic drug granules coated with polyoxyalkylene glycol
US6001390 *Dec 18, 1996Dec 14, 1999Alza CorporationFormulations for transdermal delivery of pergolide
US6004578 *Oct 23, 1997Dec 21, 1999Alza CorporationFor enhancing the percutaneous absorption of drugs when administered to a body surface or membrane
US6007837 *Feb 3, 1999Dec 28, 1999Alza CorporationHeating device comprising drug-supersaturated first layer and drug-free second layer to cause controlled drug migration from first layer into second layer, rapidly cooling to yield supersaturated concentration of drug in both layers
US6054463 *Mar 17, 1999Apr 25, 2000Sepracor Inc.Methods for treating dermatitis using descarboethoxyloratadine
US6100274 *Jul 7, 1999Aug 8, 2000Schering Corporation8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6110488 *Jun 6, 1995Aug 29, 2000Lts Lohmann Therapie-Systeme Gmbh & Co. KgApplying a polymeric acrylic pressure sensitive adhesive to a detacable protective layer, applying absorbent factric to the adhesive, applying a drug and laminating a backing layer to the fabric material
US6110499 *Jul 20, 1998Aug 29, 2000Alza CorporationPhenytoin therapy
US6110973 *Jan 28, 1999Aug 29, 2000SepracorMethods for treating obesity and weight gain using optically pure (-)-bupropion
US6114346 *Oct 22, 1999Sep 5, 2000Schering CorporationTreating sleep disorders using desloratadine
US6126963 *Jun 6, 1995Oct 3, 2000Lts Lohmann Therapie-Systeme Gmbh & Co. KgBags for transdermal drug therapy
US6139868 *Jun 6, 1995Oct 31, 2000Lts Lohmann Therapie-Systeme Gmbh & Co. KgTransdermal therapeutic system, its use and production process
US6165497 *Mar 1, 1991Dec 26, 2000Alza CorporationSubsaturated nicotine transdermal therapeutic system
US6174545Feb 3, 1999Jan 16, 2001Alza CorporationDevice for the transdermal administration of testosterone through intact, non-scrotal skin over an administration period
US6190683 *Aug 28, 1997Feb 20, 2001Lintec CorporationFor removing blackhead formed on pores of human skins
US6197788Nov 26, 1998Mar 6, 2001Vernalis Research Limited(−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US6203817Jun 5, 1998Mar 20, 2001Alza CorporationReduction of skin reactions caused by transdermal drug delivery
US6238700May 5, 1998May 29, 2001Alza CorporationMethod for preventing crystal formation in a dispersion of a liquid in a matrix
US6265414May 3, 2000Jul 24, 2001Schering CorporationTreating sleep disorders using desloratadine
US6267984Dec 17, 1998Jul 31, 2001Alza CorporationImproved transdermal drug delivery
US6277887Apr 20, 2000Aug 21, 2001Sepracor, Inc.Methods for treating Parkinson's disease using optically pure (−)-bupropion
US6287598May 28, 1993Sep 11, 2001Alza CorporationMethod for providing sustained antiepileptic therapy
US6312715 *May 1, 1998Nov 6, 20013M Innovative Properties CompanyAdhesive microsphere drug delivery composition
US6331571Aug 11, 1999Dec 18, 2001Sepracor, Inc.Methods of treating and preventing attention deficit disorders
US6337328Aug 18, 2000Jan 8, 2002Sepracor, Inc.Bupropion metabolites and methods of use
US6339106Sep 14, 2000Jan 15, 2002Sepracor, Inc.Methods and compositions for the treatment and prevention of sexual dysfunction
US6342496Feb 22, 2000Jan 29, 2002Sepracor Inc.Bupropion metabolites and methods of use
US6342533Nov 30, 1999Jan 29, 2002Sepracor, Inc.Antidepressants udes for bipolar and attention deficit disorders, hyperactivity, parkinson's disease, epilepsy, eating disorders
US6348210Nov 10, 1999Feb 19, 2002Alza CorporationMethods for transdermal drug administration
US6369113Jun 27, 2001Apr 9, 2002Sepracor, Inc.Antidepressants, parkinson's disease
US6399826Jan 11, 2000Jun 4, 2002Sepracor Inc.Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6410052Aug 10, 2000Jun 25, 2002Purdue Research FoundationTea catechins in sustained release formulations as cancer specific proliferation inhibitors
US6428818Aug 17, 2000Aug 6, 2002Purdue Research FoundationDietary or nutritional supplements and therapeutics for prevention and treatment of cancer; epicatechin and epigallocatechin gallate at 10:1 ratio; gallic acid free
US6432446Feb 1, 2001Aug 13, 2002Bridge Pharma, Inc.Non-arrhythmogenic metabolite of oxybutynin
US6440457May 27, 1993Aug 27, 2002Alza CorporationAdministering venlafaxine antidepressant time-release agent; sustained release
US6451860Feb 19, 2002Sep 17, 2002Sepracor, Inc.Methods for treating depression and other disorders using optically pure (−)-bupropion
US6458374Jan 28, 1999Oct 1, 2002Sepracor, Inc.Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
US6476078Jan 29, 2001Nov 5, 2002Sepracor, Inc.Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6479073 *Oct 7, 1996Nov 12, 20023M Innovative Properties CompanyPressure sensitive adhesive articles and methods for preparing same
US6495605Mar 13, 2001Dec 17, 2002Sepracor Inc.Pure isomers
US6512010Jul 14, 1997Jan 28, 2003Alza CorporationFormulations for the administration of fluoxetine
US6538034Dec 4, 2001Mar 25, 2003Thomas P. JerussiMethods of treating or preventing weight gain, obesity, and related disorders
US6548082Feb 29, 2000Apr 15, 2003Sepracor Inc.Sleep disorders
US6559188Sep 15, 2000May 6, 2003Novartis AgMethod of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6562357Jun 7, 1999May 13, 2003Lintec CorporationBlackhead removing sheet and method for producing blackhead removing sheet
US6569448Oct 17, 1997May 27, 2003Alza CorporationMethod for preventing crystal formation in a dispersion of a liquid in a matrix
US6572879Jun 7, 1995Jun 3, 2003Alza CorporationFormulations for transdermal delivery of pergolide
US6592892Aug 29, 2000Jul 15, 2003Tepha, Inc.Flushable disposable polymeric products
US6610887Apr 12, 2002Aug 26, 2003Sepracor Inc.Reacting a polymer bound n-(1-(4-chlorophenyl)-cyclobutyl methylidene-2- methyl propane sulfinamide with a reagent capable of cleaving a nitrogen-sulfur bond
US6649183Nov 1, 2001Nov 18, 2003Sepracor Inc.Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US6660295Sep 29, 1998Dec 9, 2003Alza CorporationA pouch containing (a) a transdermal drug delivery device comprising a drug reservoir layer positioned between a release liner and a backing alyer, one of the layer being non-occlusive, (b) oxybutynin as antioxidant and desiccant
US6664397Mar 6, 1998Dec 16, 2003Vernalis Research LimitedAdministering to subject effective dose of (+)-mefloquine or pharmaceutically acceptable salt thereof substantially free of (-)-enantiomer; reduced side effects
US6699497Jul 23, 1999Mar 2, 2004Alza CorporationPermeation enhancer
US6709676Jun 19, 2002Mar 23, 2004Schering CorporationBilayer solid comprising an immediate release first layer of desloratadine, and an antioxidant or group 2a or aluminum salts and excipient, and a sustained release second layer of nasal decongestant such as pseudoephedrine sulfate
US6710087Jun 4, 2002Mar 23, 2004Sepracor, Inc.Methods of treating or preventing neuropathic pain using sibutramine metabolites
US6734213May 17, 2002May 11, 2004Smithkline Beecham CorporationAdministering (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol or salts and solvates thereof to treat alcoholism
US6770295 *Aug 26, 1999Aug 3, 2004Pharmacia AbOnce-daily administration form, while maintaining the desired effect on the bladder, indeed gives a significant reduction of the (already low) side-effects, particularly dry mouth
US6825205Sep 24, 2003Nov 30, 2004Euro-Celtique S.A.N-substituted hydromorphones and the use thereof
US6855820May 17, 2002Feb 15, 2005Smithkline Beecham CorporationTreating racemic 2-(chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol with p-toluyl-L-tartaric acid(a chiral acid) in a suitable solvent to form a mixture of diastereomeric salts; isolating the salt, reacting with base
US6858589Jul 23, 2002Feb 22, 2005Pharmacy And Therapeutic Advisory Consultancy Pty LtdMethods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US6878713Dec 12, 2002Apr 12, 2005Wockhardt LimitedGeneration triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878749Jan 16, 2003Apr 12, 2005Novartis AgMethod of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6894189Aug 20, 2003May 17, 2005Sepracor Inc.Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6911479Aug 19, 2002Jun 28, 2005Sepracor Inc.Side effect reduction; purity; removal of stereoisomers
US6951873Mar 3, 2000Oct 4, 2005Pfizer Inc.Cognitive dysfunction syndrome in cats and dogs; substituted piperidines, fused heterocycles
US6964966Apr 23, 2002Nov 15, 2005Wockhardt LimitedSuch as 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid for treatment of systemic or topical infections
US6974837Oct 23, 2002Dec 13, 2005Sepracor Inc.Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
US6974838Mar 23, 2004Dec 13, 2005Sepracor Inc.dopamine reuptake inhibitors; for treatment of thoratic outlet obstruction syndrome
US6979463Jun 19, 2002Dec 27, 2005Schering CorporationStable extended release oral dosage composition
US6995168May 29, 2003Feb 7, 2006Euro-Celtique S.A.such as 5-[8-(3-dimethylcarbamoyl-3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-pentanoic acid; side effect reduction; for stimulating opioid receptors
US6998400May 17, 2002Feb 14, 2006Smithkline Beecham CorporationPharmaceutically active morpholinol
US7011844Nov 22, 2002Mar 14, 2006Alza CorporationFormulations for the administration of fluoxetine
US7019030Jul 17, 2003Mar 28, 2006Celgene CorporationImmunotherapeutic agents
US7034059Jun 28, 2002Apr 25, 2006Sepracor Inc.Reducing production of PGE2; treating autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, and cancer
US7063859Sep 18, 2002Jun 20, 2006Noven Pharmaceuticals, Inc.Barrier film lined backing layer composition and method for topical administration of active agents
US7071234Mar 25, 2003Jul 4, 2006Sepracor Inc.Methods of treating or preventing erectile dysfunction
US7078526May 30, 2003Jul 18, 2006Transform Pharmaceuticals, Inc.Crystal structured fungicides selected from itraconazole, posaconazole or saperconazole used for prevention or prophylaxis of fungi, yeasts and dermatophyte infections
US7094422Aug 20, 2003Aug 22, 2006Acrux Dds Pty Ltd.With dermal penetration enhancer, octyl salicylate
US7098206May 17, 2002Aug 29, 2006Smithkline Beecham CorporationPsychological disorders; antidepressants;
US7105333Mar 27, 2002Sep 12, 2006Deadreon CorporationNucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7112430May 14, 2002Sep 26, 2006Dendreon CorporationNucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7125703Mar 13, 2002Oct 24, 2006Dendreon CorporationNucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7141696May 21, 2004Nov 28, 2006Bridge Pharma, Inc.N-alkyl-diphenyl-alkylene-amine derivatives; for the treatment of smooth muscle hyperactivity in urinary incontinence, gastrointestinal disorder, respiratory system disorder; promoting smooth muscle relaxation, reducing hypotension or cardiac side effects
US7164023Dec 31, 2003Jan 16, 2007Wockhardt LimitedBenzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
US7169409Sep 8, 2003Jan 30, 2007Alza CorporationHeating film or laminate of a transdermal delivery device which comprises a dispersion of liquid drug in a matrix immediately following film formation or lamination; maintaining heat; cooling
US7172892Mar 20, 2002Feb 6, 2007Dendreon CorporationExhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers
US7176218Jan 7, 2005Feb 13, 2007Aryx TherapeuticsStereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7182953Dec 11, 2000Feb 27, 2007Celgene CorporationMethods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US7186863May 21, 2004Mar 6, 2007Transform Pharmaceuticals, Inc.Sertraline compositions
US7189740Apr 11, 2003Mar 13, 2007Celgene Corporationsynergistic mixture of amino-1,3-dihydroisoindol-2-yl)piperidin-2,6-dione compound as immunomoderator and another active drug
US7205413May 1, 2003Apr 17, 2007Transform Pharmaceuticals, Inc.Comprises formamide solvent; for treatment of HIV/inhibiting proteases; crystal structure; kits
US7211582Nov 23, 1999May 1, 2007Sepracor Inc.Effective, non-sedating antihistamine for treating allergic rhinitis; avoiding adverse side-effects
US7214683Mar 16, 1998May 8, 2007Sepracor Inc.Compositions of descarboethoxyloratadine
US7214684Nov 17, 2004May 8, 2007Sepracor Inc.Administering to a human a therapeutically effective amount of descarboethoxyloratadine
US7229640Dec 18, 2001Jun 12, 2007Smithkline Beecham P.L.C.Paroxetine controlled release compositions
US7259152Jun 4, 2001Aug 21, 2007Alfa Wasserman, Inc.Oral administration of Sulodexide in unit dosages suitable for the treatment of diabetic nephropathies in both macro and micro albuminic patients, producing immediate and lasting improvement in albumin excretion rate
US7276364Nov 20, 2000Oct 2, 2007Dendreon CorporationNucleic acids encoding endotheliases, endotheliases and uses thereof
US7282509Mar 23, 2005Oct 16, 2007Aryx TherapeuticsStereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7291347Jan 18, 2006Nov 6, 2007WyethSolubility, permeability, and bioavailability; oral dosage
US7323479Nov 6, 2003Jan 29, 2008Celgene CorporationImmunomodulators; side effect reduction
US7323480May 24, 2005Jan 29, 2008Metabolex, Inc.Diseases mediated by Peroxisome Proliferator-Activated Receptors such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, risk factors for cardiovascular disease, Syndrome X
US7326787Aug 31, 2006Feb 5, 2008Aryx Therapeutics, Inc.Preparing (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate; ethyl 4-amino-3-methoxypiperidine-1-carboxylate; benzylation; chiral salt; basification; ethyl 6-bromohexanoate; R)-quinuclidin-3-ol; deprotect; 4-amino-5-chloro-2-methoxybenzoic acid
US7329761Nov 16, 2004Feb 12, 2008Celgene CorporationSubstituted imides
US7351739Apr 29, 2005Apr 1, 2008Wellgen, Inc.Bioactive compounds and methods of uses thereof
US7354948Nov 6, 2003Apr 8, 2008Celgene CorporationMethods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US7358246Apr 7, 2005Apr 15, 2008Wyeth5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbothioamide; contraceptive, menopause; reduces risk of uterine cancers coused by treating with estrogen receptor (ER) agonists
US7393862Oct 4, 2005Jul 1, 2008Celgene CorporationImmunomodulators; chemotherapy, radiation therapy, hormonal therapy, biological therapy, immunotherapy
US7393863Jan 16, 2007Jul 1, 2008Celgene CorporationMethods of using N-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide for the treatment and management of myelodysplastic syndromes
US7393957Sep 20, 2004Jul 1, 2008Wockhardt LimitedGeneration triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US7405223Jan 16, 2001Jul 29, 2008Schering CorporationTreating allergic and inflammatory conditions
US7414062Jun 16, 2005Aug 19, 2008Purdue Pharma L.P.such as 5-[8-(3-dimethylcarbamoyl-3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-pentanoic acid; non-opioid analgesic; side effect reduction; for stimulating opioid receptors
US7438903May 7, 2004Oct 21, 2008Nbty, Inc.Fine particle sizes; nanostructure; in mixture with oil, water carriers, excipients; oral diseases; cognition activators; hypotensive agents; immunology diseases; blood disorders
US7446107Aug 26, 2004Nov 4, 2008Transform Pharmaceuticals, Inc.Soluble crystalline form of cis-itraconazole, posaconazole or saperconazole comprising the reaction product of cis-itraconazole, posaconazole or saperconazole and an organic acid or an inorganic acid; use in treating or preventing local and systemic fungal, yeast, and dermatophyte infections
US7465800Sep 3, 2004Dec 16, 2008Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7468363Apr 8, 2005Dec 23, 2008Celgene CorporationImmunomodulators; side effect reduction; non-Hodgkin's lymphoma, myelogenous leukemia, amyloidosis, and cancer of ovaries, pancreas, kidneys
US7470435Nov 17, 2003Dec 30, 2008Andrx Pharmaceuticals, LlcPellets containing binder
US7511071Mar 7, 2008Mar 31, 2009WyethThioamide derivatives as progesterone receptor modulators
US7514466Apr 25, 2005Apr 7, 2009WyethPurification of progesterone receptor modulators
US7514583May 30, 2003Apr 7, 2009Proteotech, Inc.Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US7518017Jan 31, 2007Apr 14, 2009Idexx LaboratoriesFenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US7553923Oct 26, 2007Jun 30, 2009Metabolix, Inc.Medical devices and applications of polyhydroxyalkanoate polymers
US7572812Jan 20, 2006Aug 11, 2009Purdue Pharma, L.P., UsaTreating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis
US7582635Dec 19, 2003Sep 1, 2009Purdue Pharma, L.P.Benzoazolylpiperazine compounds inhibition of gluatmate receptors; for treatment of urinary incontinence, ulcers, irritable-bowel syndrome, inflammatory-bowel disease, addictive disorders, Parkinson's disease, parkinsonism, anxiety, epilepsy; kits
US7592335Apr 12, 2006Sep 22, 2009Ranbaxy Laboratories Limited3-{3-fluoro-4-[(7aE)-hexahydropyrrolo[3,4-b][1,4]oxazin-4(4aH)-yl]phenyl}-5-(iodomethyl)-1,3-oxazolidin-2-one; antibiotics; preventing catheter infections; good activity against multiply resistant gram positive pathogens
US7612096Apr 23, 2004Nov 3, 2009Celgene CorporationMethods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US7618649Nov 3, 2003Nov 17, 2009Schering CorporationFor therapy of nasal and non-nasal symptoms of perennial and seasonal allergic rhinitis
US7622136Jun 18, 2004Nov 24, 2009Alza CorporationTransparent transdermal nicotine delivery devices
US7626032Apr 24, 2008Dec 1, 2009Wockhardt Limited4-Amino-3,3-dimethylpiperidine; reduced toxicity, and improved pharmacology and pharmacokinetics
US7629466Apr 25, 2008Dec 8, 2009Aryx Therapeutics, Inc.Preparing (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate; ethyl 4-amino-3-methoxypiperidine-1-carboxylate; benzylation; chiral salt; basification; ethyl 6-bromohexanoate; R)-quinuclidin-3-ol; deprotect; 4-amino-5-chloro-2-methoxybenzoic acid
US7641825Jul 29, 2005Jan 5, 2010Tepha, Inc.Method of making a polyhydroxyalkanoate filament
US7642287Aug 5, 2005Jan 5, 2010Transform Pharmaceuticals, Inc.storage stable drug contains pravastatin calcium and an omega-3 oil, wherein the omega-3 oil comprises 46% ethyl ester of eicosapentaenoic acid, 38% ethyl ester of docosahexaenoic acid; anticholesterol agent, antilipemic agent; treating atherosclerosis, hyperlipidemia, cardiovascular disease
US7659265Feb 12, 2009Feb 9, 2010Wyeth5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbothioamide; menopause therapy; contraceptive; anticancer agents
US7659282Jan 12, 2005Feb 9, 2010Avanir Pharmaceuticals, Inc.Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US7659287May 31, 2007Feb 9, 2010Amgen Inc.Benzamide derivatives and uses related thereto
US7671093May 27, 2005Mar 2, 2010Transform Pharmaceuticals, Inc.Mixed co-crystals and pharmaceutical compositions comprising the same
US7683063Jun 14, 2004Mar 23, 2010Purdue Pharma L.P.inhibiting Vanilloid Receptor 1; Inflammatory bowel disease; Crohn's disease and ulcerative colitis; cyclo(hetero)alkenyl compound
US7696208Jan 31, 2006Apr 13, 2010Purdue Pharma L.P.4-(2-Pyridyl)-1-amino(thio)carbonylpiperazine derivatives are inhibitors of VR1 expression in a cell
US7700341Feb 2, 2001Apr 20, 2010Dendreon CorporationNucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7728025Dec 28, 2004Jun 1, 2010Banyu Pharmaceutical Co., Ltd.Glucokinase activators as antidiabetic, antiobesity agents; 5-(4-methanesulfonyl-phenoxy)-2-pyrazin-2-yl-6-(2-carbamoyl-phenoxy)-1H-benzimidazole for example
US7754723Jun 28, 2006Jul 13, 2010Purdue Pharma, L.P., UsaTherapeutic agents useful for treating pain
US7767429Mar 5, 2004Aug 3, 2010Halozyme, Inc.use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms; HYLENEX RECOMBINANT tradename
US7767699Dec 22, 2005Aug 3, 2010Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US7772206Feb 27, 2009Aug 10, 2010Genzyme CorporationMethods and compositions for the treatment of autoimmune disorders using clofarabine
US7772254Mar 21, 2006Aug 10, 2010Purdue Pharma L.P.Pyridylene compounds used as analgesics and for inhibiting Vanilloid Receptor 1 and metabotropic glutamate receptor 1 function in a cells
US7776861Jan 23, 2006Aug 17, 2010Purdue Pharma L.P.Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants
US7776907Oct 30, 2003Aug 17, 2010Celgene CorporationMethods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US7790905Dec 29, 2003Sep 7, 2010Mcneil-Ppc, Inc.sodium salt of celecoxib
US7799807Mar 20, 2006Sep 21, 2010Purdue Pharma L.P.vanilloid receptor antagonists comprising phenylene compounds, used as analgesic
US7799820Sep 29, 2006Sep 21, 2010Banyu Pharmaceutical Co., Ltd.glucokinase activators such as 7-(2-fluorophenoxy)-5-(4-(methylsulfonyl)phenoxy)-2-pyridin-2-yl-1H-indole, used as dietetics and/or antidiabetic agents
US7803366Aug 25, 2008Sep 28, 2010Nbty, Inc.Methods and compositions that enhance bioavailability of coenzyme-Q10
US7803786Jun 16, 2005Sep 28, 2010Transform Pharmaceuticals, Inc.Pharmaceutical co-crystal compositions and related methods of use
US7812169Nov 30, 2001Oct 12, 2010The Children's Medical Center CorporationAngiogenesis inhibitors; vision defects; anticancer agents; retinopathy; skin disorders; antiarthritic agents; antitumor agents; aids
US7820199Oct 6, 2005Oct 26, 2010Schering Corporationfor therapy of allergic and/or inflammatory conditions of the skin and airway passages; desloratadine-pseudoephedrine once-a-day product which produces a release rate profile for pseudoephedrine over an extended period in excess of twelve hours while maintaining delivery of desloratadine
US7829081Mar 4, 2010Nov 9, 2010Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7842691Apr 13, 2003Nov 30, 2010Celgene CorporationMethod for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US7846431Mar 4, 2010Dec 7, 2010Halozyme, Inc.Composition comprising hyaluronidase glycoprotein that is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine for use in treatment of diabetic disorders
US7855217Dec 15, 2008Dec 21, 2010Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7863297Nov 12, 2007Jan 4, 2011Celgene CorporationMethods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes
US7871607Feb 23, 2005Jan 18, 2011Halozyme, Inc.use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant soluble neutral active Hyaluronidase Glycoproteins to enhance stability and serum pharmacokinetics over natural slaughterhouse enzymes; transgenic animals; dosage forms
US7879846Sep 20, 2007Feb 1, 2011Kyorin Pharmaceutical Co.., Ltd.Serine hydrolase inhibitors
US7883487Dec 18, 2008Feb 8, 2011Shantha Totada RTransdermal local anesthetic patch with injection port
US7888092Oct 30, 2009Feb 15, 2011Dendreon CorporationNucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7892776May 5, 2008Feb 22, 2011The Regents Of The University Of CaliforniaScreening assay to identify modulators of protein kinase A
US7893045Aug 5, 2008Feb 22, 2011Celgene CorporationMethods for treating lymphomas in certain patient populations and screening patients for said therapy
US7902208May 30, 2008Mar 8, 2011Schering CorporationTreating allergic and inflammatory conditions
US7927613Sep 11, 2003Apr 19, 2011University Of South FloridaPharmaceutical co-crystal compositions
US7928132Aug 6, 2004Apr 19, 2011Ohio UniversityMethods for the amelioration of episodes of acute or chronic ulcerative colitis
US7931915Nov 19, 2008Apr 26, 2011Andrx Pharmaceuticals, LlcExtended release venlafaxine formulation
US7932421Dec 12, 2007Apr 26, 2011Amgen Inc.N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
US7943683Oct 31, 2007May 17, 2011Tepha, Inc.Thin bioabsorbable materials; toughness, low modulus, tensile strength; tissue repair, drug delivery and support; solvent casting or melt extrusion continuous production
US7964606Jul 29, 2010Jun 21, 2011Purdue Pharma L.P.Therapeutic agents useful for treating pain
US7968569May 15, 2003Jun 28, 2011Celgene CorporationAnticancer agents; angiogenesis inhibitor; side effect reduction
US7977357Jul 23, 2008Jul 12, 2011Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindo1-2-yl)-piperidine-2,6-dione
US7994177Jul 21, 2010Aug 9, 2011Purdue Pharma L.P.Therapeutic agents useful for treating pain
US8008300Jul 8, 2009Aug 30, 2011Purdue Pharma L.P.Therapeutic agents useful for treating pain
US8017598May 16, 2007Sep 13, 2011Knopp Neurosciences, Inc.Compositions of R(+) and S(−) pramipexole and methods of using the same
US8026254Nov 10, 2009Sep 27, 2011Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US8030310Mar 2, 2010Oct 4, 2011Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US8034270Apr 30, 2004Oct 11, 2011Tepha, Inc.Polyhydroxyalkanoate medical textiles and fibers
US8058292May 24, 2010Nov 15, 2011Purdue Pharma L.P.Therapeutic agents useful for treating pain
US8058443Dec 15, 2008Nov 15, 2011Celgene Corporationmaking crystalline lenalidomide
US8063221Mar 13, 2007Nov 22, 2011Kyorin Pharmaceutical Co., Ltd.Aminoquinolones as GSK-3 inhibitors
US8071591Mar 10, 2010Dec 6, 2011Kyorin Pharmaceutical Co., Ltd.7-cycloalkylaminoquinolones as GSK-3 inhibitors
US8075911Aug 20, 2007Dec 13, 2011Alza CorporationTransparent transdermal nicotine delivery devices
US8084059Sep 15, 2006Dec 27, 2011Alza CorporationAntidepressant dosage form
US8084125Dec 11, 2009Dec 27, 2011Tepha, Inc.Non-curling polyhydroxyalkanoate sutures
US8101745Dec 15, 2005Jan 24, 2012The Regents Of The University Of CaliforniaConjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers
US8105586Jun 15, 2010Jan 31, 2012Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8110602Jul 15, 2009Feb 7, 2012Purdue Pharma L.P.Compounds comprising heterocyclic-substituted piperidine for treating pain
US8129388Jun 10, 2011Mar 6, 2012Purde Pharma L.P.Therapeutic agents useful for treating pain
US8138204Jul 16, 2007Mar 20, 2012Aryx Therapeutics, Inc.Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts
US8138361Dec 27, 2006Mar 20, 2012The Trustees Of The University Of PennsylvaniaC-10 carbamates of taxanes
US8143286Dec 15, 2008Mar 27, 2012Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione)
US8153162Sep 27, 2006Apr 10, 2012Tissuetech, Inc.Purified amniotic membrane compositions and methods of use
US8153806Jul 16, 2010Apr 10, 2012The Children's Medical Center CorporationSynthesis of 4-amino-thalidomide enantiomers
US8163957Jul 16, 2010Apr 24, 2012Proteotech, Inc.Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
US8168635Jun 20, 2005May 1, 2012Human Biomolecular Research InstituteModulators of central nervous system neurotransmitters
US8168672Feb 2, 2010May 1, 2012WyethThioamide derivatives as progesterone receptor modulators
US8178560Jun 17, 2010May 15, 2012Purdue Pharma L.P.Therapeutic agents useful for treating pain
US8182840Sep 27, 2006May 22, 2012Tissue Tech, Inc.Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8182841Sep 27, 2006May 22, 2012Tissue Tech, Inc.Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8183290Jul 20, 2010May 22, 2012Mcneil-Ppc, Inc.Pharmaceutically acceptable propylene glycol solvate of naproxen
US8183381Jul 10, 2008May 22, 2012Metabolex Inc.N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8187630Oct 2, 2009May 29, 2012Schering-Plough CorporationExtended release oral dosage composition
US8187639Sep 27, 2006May 29, 2012Tissue Tech, Inc.Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8188118Feb 19, 2009May 29, 2012Celgene CorporationMethod for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies
US8193219Oct 3, 2011Jun 5, 2012Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8198262Aug 19, 2008Jun 12, 2012Celgene CorporationMethods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US8198306Dec 17, 2009Jun 12, 2012Celgene CorporationMethods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a proteasome inhibitor
US8202517Feb 20, 2009Jun 19, 2012Halozyme, Inc.Use to degrade glycosaminoglycans in a tissue to aid in drug delivery of various drugs and biodrugs
US8202999Jan 6, 2006Jun 19, 2012Synta Pharmaceuticals Corp.Compounds for inflammation and immune-related uses
US8207200May 8, 2008Jun 26, 2012Celgene Corporationreducing side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy; administration of an immunomodulatory compound; cancer
US8211428Jul 5, 2007Jul 3, 2012Torrey Pines Institute For Molecular StudiesProtease screening methods and proteases identified thereby
US8219168Apr 13, 2004Jul 10, 2012Abbott Diabetes Care Inc.Article and method for applying a coupling agent for a non-invasive optical probe
US8222257Mar 30, 2006Jul 17, 2012The Regents Of The University Of CaliforniaPhosphono-pent-2-en-1-yl nucleosides and analogs
US8227467Feb 16, 2010Jul 24, 2012Purdue Pharma L.P.Therapeutic agents useful for treating pain
US8227484Mar 8, 2012Jul 24, 2012Avanir Pharmaceuticals, Inc.Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US8236288Jan 6, 2012Aug 7, 2012Skinmedica, Inc.Melanin modification compositions and methods of use
US8241662Dec 21, 2006Aug 14, 2012Watson Laboratories, Inc.Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
US8247423Jul 11, 2008Aug 21, 2012Tragara Pharmaceuticals, Inc.Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US8257699Dec 15, 2011Sep 4, 2012Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8263637May 16, 2003Sep 11, 2012Celgene CorporationMethods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide
US8269040Nov 25, 2003Sep 18, 2012Wyeth LlcO-desmethylvenlafaxine succinate; tablet, capsule; sustained release; hydroxypropylmethyl cellulose rate controlling polymer; microcrystalline cellulose binder; depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease
US8273361Sep 26, 2007Sep 25, 2012Infectious Disease Research InstituteGlucopyranosyl lipid adjuvant; toll-like receptors; saponins; kits
US8288384Nov 16, 2009Oct 16, 2012Metabolex, Inc.Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8299117Jun 16, 2010Oct 30, 2012Metabolex Inc.GPR120 receptor agonists and uses thereof
US8304418May 28, 2008Nov 6, 2012Agennix AgPyrazolopyrimidinone kinase inhibitor
US8309594Feb 12, 2009Nov 13, 2012Wyeth LlcPurification of progesterone receptor modulators
US8309600Dec 17, 2009Nov 13, 2012Metabolex Inc.GPR120 receptor agonists and uses thereof
US8314130Oct 1, 2009Nov 20, 2012Synta Pharmaceuticals Corp.Compounds inclunding substituted pyridines for inflammation and immune-related uses
US8314134Mar 5, 2010Nov 20, 2012Synta Pharmaceuticals Corp.Compounds for inflammation and immune-related uses
US8318700Jan 18, 2012Nov 27, 2012The Regents Of The University Of CaliforniaLung-targeted drugs
US8343512Oct 20, 2011Jan 1, 2013Infectious Disease Research InstituteTreatment of allergic conditions using a composition containing synthetic adjuvant
US8349842Jul 20, 2009Jan 8, 2013Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US8349851Feb 26, 2010Jan 8, 2013Ambit Biosciences Corp.JAK kinase modulating compounds and methods of use thereof
US8361272Jun 27, 2007Jan 29, 2013Ferring B.V.Polyurethane elastomers
US8361273Sep 6, 2012Jan 29, 2013Ferring B.V.Polyurethane elastomers
US8362062Dec 24, 2003Jan 29, 2013Mcneil-Ppc, Inc.Pharmaceutical compositions with improved dissolution
US8377979Dec 5, 2006Feb 19, 2013Taro Pharmaceuticals North America, Inc.Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
US8383149Sep 22, 2006Feb 26, 2013Alza CorporationHigh enhancer-loading polyacrylate formulation for transdermal applications
US8389514Sep 11, 2008Mar 5, 2013Kyorin Pharmaceutical Co., Ltd.Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
US8389549Apr 25, 2008Mar 5, 2013Purdue Pharma L.P.Substituted pyridines useful for treating pain
US8394807Nov 20, 2009Mar 12, 2013Purdue Research FoundationQuinazoline inhibitors of BACE 1 and methods of using
US8404716May 11, 2010Mar 26, 2013Celgene CorporationMethods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717Mar 24, 2011Mar 26, 2013Celgene CorporationMethods of treating myelodysplastic syndromes using lenalidomide
US8404728Jul 29, 2010Mar 26, 2013Mayo Foundation For Medical Education And ResearchSmall-molecule botulinum toxin inhibitors
US8410127Sep 20, 2010Apr 2, 2013Metabolex, Inc.Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8410136Apr 7, 2010Apr 2, 2013Celgene CorporationMethods for treatment of hepatocellular carcinoma using 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
US8415294Jun 5, 2008Apr 9, 2013Arizona Board Of RegentsCyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
US8419793 *Mar 12, 2010Apr 16, 2013Mentor Worldwide LlcCoating with antimicrobial agents
US8420126Apr 23, 2012Apr 16, 2013Tissue Tech, Inc.Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8420153 *Sep 19, 2008Apr 16, 2013Mentor Worldwide LlcCoating with antimicrobial agents
US8431124Apr 16, 2009Apr 30, 2013Halozyme, Inc.Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
US8431380Feb 20, 2009Apr 30, 2013Halozyme, Inc.facilitate drug delivery of other molecules; e.g. use intraocularly in eye surgery, glaucoma, retinopathy treatments
US8431598May 26, 2011Apr 30, 2013Celgene CorporationPolymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8440194Feb 19, 2008May 14, 2013Celgene CorporationAngiogenesis inhibitors; immunomodulators; side effect reduction
US8440235Apr 23, 2012May 14, 2013Tissuetech, Inc.Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8440705Sep 16, 2005May 14, 2013Whitehead Institute For Biomedical ResearchCompounds, compositions and methods of inhibiting alpha-synuclein toxicity
US8445474Aug 5, 2011May 21, 2013Knopp Neurosciences, Inc.Compositions of R(+) and S(−) pramipexole and methods of using the same
US8450470Jun 3, 2009May 28, 2013Halozyme, Inc.Use to faciliate drug delivery of other drugs, or treat glycosaminoglycan associated pathologies, such as scarring, spinal cord injury, glaucoma, and cosmetic treatments
US8455009Apr 23, 2012Jun 4, 2013Tissuetech, Inc.Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8455658Jan 25, 2007Jun 4, 2013Synta Pharmaceuticals Corp.Thiazole and thiadiazole compounds for inflammation and immune-related uses
US8460707Mar 26, 2012Jun 11, 2013Ferring B.V.Stabilised prostaglandin composition
US8460714Apr 3, 2012Jun 11, 2013Tissuetech, Inc.Purified amniotic membrane compositions and methods of use
US8470817Oct 26, 2010Jun 25, 2013Sunesis Pharmaceuticals, Inc.Compounds and methods for treatment of cancer
US8476261Sep 12, 2008Jul 2, 2013Kyorin Pharmaceutical Co., Ltd.Spirocyclic aminoquinolones as GSK-3 inhibitors
US8476271Jan 20, 2011Jul 2, 2013Purdue Pharma, L.P.Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US8476277Apr 25, 2008Jul 2, 2013Purdue Pharma L.P.TRPV1 antagonists including dihydroxy substituent and uses thereof
US8476308Oct 4, 2012Jul 2, 2013Metabolex, Inc.GPR120 receptor agonists and uses thereof
US8481501May 31, 2005Jul 9, 2013Human Biomolecular Research InstituteSynthesis of metabolically stable analgesics, pain medications and other agents
US8486668Aug 4, 2011Jul 16, 2013Ritter Pharmaceuticals, Inc.Prebiotic formulations and methods of use
US8491934Jul 28, 2005Jul 23, 2013Ferring B.V.Stabilised prostaglandin composition
US8492124Feb 17, 2010Jul 23, 2013Ritter Pharmaceuticals, Inc.Prebiotic formulations and methods of use
US8492406Apr 7, 2010Jul 23, 2013Celgene CorporationMethods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
US8492423Apr 3, 2012Jul 23, 2013Mcneil-Ppc, Inc.Pharmaceutical propylene glycol solvate compositions
US8492428Sep 20, 2006Jul 23, 2013Mayo Foundation For Medical Education And ResearchSmall-molecule botulinum toxin inhibitors
US8518926Dec 14, 2007Aug 27, 2013Knopp Neurosciences, Inc.Compositions and methods of using (R)-pramipexole
US8518950Jan 25, 2006Aug 27, 2013Synta Pharmaceuticals Corp.2-amido pyrazines for inflammation and immune related uses
US8518958Oct 16, 2007Aug 27, 2013Forma Therapeutics, Inc.Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
US8519148Mar 14, 2008Aug 27, 2013Knopp Neurosciences, Inc.Synthesis of chirally purified substituted benzothiazole diamines
US8524254Oct 15, 2007Sep 3, 2013Ferring B.V.Bioresorbable polymers
US8524695Mar 14, 2008Sep 3, 2013Knopp Neurosciences, Inc.Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8524736Feb 10, 2012Sep 3, 2013Armetheon, Inc.Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524756Oct 16, 2012Sep 3, 2013Synta Pharmaceuticals Corp.Compounds for inflammation and immune-related uses
US8530498Apr 8, 2013Sep 10, 2013Celgene CorporationMethods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
US8536177Aug 8, 2011Sep 17, 2013Purdue Pharma L.P.Therapeutic agents useful for treating pain
US8546388Oct 22, 2009Oct 1, 2013Purdue Pharma L.P.Heterocyclic TRPV1 receptor ligands
US8557281Jul 13, 2010Oct 15, 2013Ferring B.V.Water-swellable polymers
US8580252Jul 6, 2012Nov 12, 2013Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8586726Jan 15, 2010Nov 19, 2013The Trustees Of Columbia University In The City Of New YorkTissue-specific MicroRNAs and compositions and uses thereof
US8592445Jun 22, 2012Nov 26, 2013Map Pharmaceuticals, Inc.Iso-ergoline derivatives
US8592486May 14, 2012Nov 26, 2013Synta Pharmaceuticals Corp.Compounds for inflammation and immune-related uses
US8598374Oct 5, 2012Dec 3, 2013Metabolex, Inc.GPR120 receptor agonists and uses thereof
US8604035Jun 22, 2012Dec 10, 2013Map Pharmaceuticals, Inc.Fluoroergoline analogs
US8604037Aug 18, 2011Dec 10, 2013Purdue Pharma, L.P.Therapeutic agents useful for treating pain
US8609114Aug 30, 2012Dec 17, 2013Infectious Diesease Research InstituteMethods of using a vaccine composition containing synthetic adjuvant
US8609712Sep 14, 2012Dec 17, 2013Wyeth LlcPurification of progesterone receptor modulators
US8618289Mar 17, 2009Dec 31, 2013Ambit Biosciences CorporationRAF kinase modulator compounds and methods of use thereof
US8623384May 8, 2013Jan 7, 2014Celgene CorporationMethods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of acute myelogenous leukemia
US8628798Aug 10, 2012Jan 14, 2014Ferring B.V.Water-swellable polymers
US8632787Dec 2, 2011Jan 21, 2014Celgene CorporationMethods using immunomodulatory compounds for treatment of certain leukemias
US8632800May 12, 2006Jan 21, 2014Alza CorporationMultilayer drug delivery system with barrier against reservoir material flow
US8633207Aug 31, 2011Jan 21, 2014Ambit Biosciences CorporationQuinazoline compounds and methods of use thereof
US8637087Nov 23, 2009Jan 28, 2014Jb Therapeutics Inc.Treatment of interstitial cystitis using (6aR, 10aR)-Δ8-tetrahydrocannabinol-11-OIC acids
US8637502Jan 12, 2012Jan 28, 2014Purde Pharma L.P.2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain
US8637548Sep 21, 2010Jan 28, 2014Purdue Pharma L.P.Therapeutic agents useful for treating pain
US8642662May 25, 2012Feb 4, 2014Sunovion Pharmaceuticals Inc.Methods of using derivatives of (−)-venlafaxine
US8648095Jun 5, 2012Feb 11, 2014Celgene CorporationMethods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor
US8653066Oct 9, 2007Feb 18, 2014Charleston Laboratories, Inc.Pharmaceutical compositions
US8663633Jul 2, 2012Mar 4, 2014Torrey Pines Institute For Molecular StudiesProtease screening methods and proteases identified thereby
US8663680Dec 5, 2011Mar 4, 2014Alza CorporationTransparent transdermal nicotine delivery devices
US8668932Mar 18, 2011Mar 11, 2014Andrx Pharmaceuticals, LlcExtended release venlafaxine formulation
US8672911Feb 2, 2009Mar 18, 2014Kimberly-Clark Worldwide, Inc.Body adhering absorbent article
US8673939Mar 1, 2013Mar 18, 2014Celgene CorporationMethods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US8680118Jun 18, 2012Mar 25, 2014Purdue Pharma L.P.Therapeutic agents useful for treating pain
US8702672Feb 2, 2009Apr 22, 2014Kimberly-Clark Worldwide, Inc.Body adhering absorbent article
US8703947Oct 9, 2009Apr 22, 2014Purdue Research FoundationCompounds for treatment of Alzheimer's disease
US8703962Oct 22, 2009Apr 22, 2014Purdue Pharma L.P.Monocyclic compounds and their use as TRPV1 ligands
US8709482May 31, 2013Apr 29, 2014Ferring B.V.Stabilised prostaglandin composition
US8710083Mar 29, 2010Apr 29, 2014Synta Pharmaceuticals Corp.Pyridylphenyl compounds for inflammation and immune-related uses
US8710092Dec 23, 2010Apr 29, 2014Map Pharmaceuticals, Inc.Substituted indolo 4,3 FG quinolines useful for treating migraine
US8710236Apr 8, 2011Apr 29, 2014Metabasis Therapeutics, Inc.Antagonists of the glucagon receptor
US8722064Jun 4, 2010May 13, 2014Infectious Disease Research InstituteSynthetic glucopyranosyl lipid adjuvants
US8722647May 30, 2012May 13, 2014Celgene CorporationMethods for treating amyloidosis using 4-(amino)-2-(2,6-Dioxo(3-piperidyl))- isoindoline-1,3-dione
US8722699Oct 3, 2013May 13, 2014Map Pharmaceuticals, Inc.Iso-ergoline derivatives
US8722705Jul 15, 2013May 13, 2014Celgene CorporationMethods for treating diffuse large B-cell lymphoma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents
US8728522Dec 14, 2010May 20, 2014Charleston Laboratories, Inc.Pharmaceutical compositions for treating or preventing pain
US8734413Feb 2, 2009May 27, 2014Kimberly-Clark Worldwide, Inc.Packaged body adhering absorbent article
US8734415Sep 22, 2011May 27, 2014Kimberly-Clark Worldwide, Inc.Body adhering absorbent article
US8735428Mar 1, 2013May 27, 2014Celgene CorporationMethods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US8741929Nov 19, 2009Jun 3, 2014Celgene CorporationMethods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
US20060200100 *Feb 16, 2006Sep 7, 2006Rosati Coni FMethod and apparatus for supplying gas to an area
US20100121304 *Nov 10, 2008May 13, 2010Kimberly-Clark Worldwide, Inc.Multifunctional Acrylate Skin-Adhesive Composition
US20130018335 *Jan 13, 2011Jan 17, 2013Laboratoires UrgoNovel bandage including agglomerates of particles suitable for rapidly gelling or solubilising
USRE32991 *Jul 25, 1988Jul 18, 1989Thermedics, Inc.Drug dispensing wound dressing
USRE37934Feb 3, 2000Dec 10, 2002Lts Lohmann Therapie-Systeme AgTransdermal therapeutic system
USRE39588Oct 31, 1990Apr 24, 2007Alza CorporationDelays onset of drug administration; does not deliver an initial burst of drug, less likely to cause irritation; stabilizes an active drug by storing it within a transdermal therapeutic system, in form suitable for storage
USRE42126Jun 30, 2000Feb 8, 2011The Procter & Gamble Companysystem for delivering oral care substance to oral cavity comprising a removable backing strip having sufficient flexibility to be conformable to oral surface and oral care composition that forms film when applied to backing strip comprising organosiloxane resin, rheology modifier, and oral care substance
DE2642032A1 *Sep 18, 1976Mar 30, 1978Merck Patent GmbhSiliciumdioxidhaltige zubereitungen und verfahren zu ihrer herstellung
DE3500508A1 *Jan 9, 1985Sep 12, 1985Nitto Electric Ind CoPraeparat zur perkutanen verabreichung von arzneimitteln und verfahren zu dessen herstellung
DE102010053792A1Dec 8, 2010Jun 14, 2012Frank BecherDevice for germ-free keeping of surfaces, such as door handles, handrails, grip bars, handles of shopping carts and toilet seating surfaces, has flat support material and self-adhesive portion formed on one side of flat support material
DE102013107024A1Jul 4, 2013May 15, 2014Golden Biotechnology CorporationMethoden und Zusammensetzungen zum Behandeln, Modifizieren und Handhaben von Knochenkrebsschmerz
DE102013202928A1Feb 22, 2013Aug 29, 2013Golden Biotechnology CorporationVerfahren und Zusammensetzungen zum Behandeln von Krebsmetastasierung
EP0011471A1 *Nov 12, 1979May 28, 1980SMITH & NEPHEW RESEARCH LIMITEDAdhesive-coated sheet material incorporating anti-bacterial substances
EP0013606A2 *Jan 4, 1980Jul 23, 1980Key Pharmaceuticals, Inc.Drug delivery device and method for its preparation
EP0020905A1 *Apr 15, 1980Jan 7, 1981C.H. Boehringer SohnPharmaceutical composition in the form of a polyacrylate film, and its preparation
EP0023395A1 *Jul 2, 1980Feb 4, 1981Minnesota Mining And Manufacturing CompanyPressure-sensitive adhesive having a broad spectrum anti-microbial therein
EP0040861A1 *Jan 4, 1980Dec 2, 1981Key Pharmaceuticals, Inc.Polymeric diffusion matrix and method of its preparation
EP0040862A1 *Jan 4, 1980Dec 2, 1981Key Pharmaceuticals, Inc.Burn matrix, method of its preparation and delivery device comprising said matrix
EP0055023A2 *Nov 16, 1981Jun 30, 1982E.R. Squibb & Sons, Inc.Antiseptic containing adhesive composition
EP0184910A2 *Nov 15, 1985Jun 18, 1986Hercon Laboratories CorporationDevice for controlled release drug delivery
EP0206741A2Jun 17, 1986Dec 30, 1986Merck Frosst Canada Inc.Leukotriene antagonists
EP0239306A2Mar 18, 1987Sep 30, 1987Merck Frosst Canada Inc.Tetrahydrocarbazole esters
EP0273004A2 *Nov 16, 1987Jun 29, 1988Ciba-Geigy AgUser-activated therapeutical system
EP0279977A2 *Sep 28, 1987Aug 31, 1988Alza CorporationTransdermal administration of progesterone, estradiol esters and mixtures thereof
EP0328524A1 *Aug 28, 1987Aug 23, 1989Univ RutgersTransdermal fertility control system and process.
EP0399765A2 *May 21, 1990Nov 28, 1990Advanced Polymer Systems, Inc.System for transdermal drug delivery
EP0480716A1Oct 10, 1991Apr 15, 1992Merck Frosst Canada Inc.Saturated hydroxyalkylquinoline acids as leukotriene antagonists
EP0484543A1 *Apr 23, 1991May 13, 1992Teijin LimitedPlaster
EP1602369A2Aug 23, 2000Dec 7, 2005Sepracor, Inc.Bupropion Metabolites and Methods of their Synthesis and Use
EP1674068A1Feb 19, 1997Jun 28, 2006Acrux DDS Pty LtdDermal penetration enhancers and drug delivery systems involving same
EP1712232A1Dec 11, 1995Oct 18, 2006Sepracor, Inc.Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
EP1759701A2Feb 29, 2000Mar 7, 2007Sepracor, Inc.Buproprion Metabolites and Methods of Their Synthesis and Use.
EP1867644A1Jul 23, 2004Dec 19, 2007Euro-Celtique S.A.Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
EP1889614A2Aug 22, 2000Feb 20, 2008APBI Holdings, LLCMethods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
EP1900369A1Apr 13, 2003Mar 19, 2008Celgene CorporationMethods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
EP1967189A1Feb 18, 2005Sep 10, 2008GPC Biotech AGMethods for treating resistant or refractory tumors
EP1980252A2Jul 17, 2003Oct 15, 2008Avanir PharmaceuticalsPharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP2002827A2Oct 31, 2002Dec 17, 2008The Baylor College Of MedicineMethods and compositions for control of bone formation via modulation of sympathetic tone
EP2011507A2Sep 15, 2000Jan 7, 2009Novartis AGPharmaceutical composition of nateglinide and another antidiabetic agent
EP2016942A1Dec 13, 2000Jan 21, 2009Celgene CorporationMethods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
EP2017276A1Sep 21, 2004Jan 21, 2009Euro-Celtique S.A.Phenyl-carboxamide compounds useful for treating pain
EP2030620A1May 8, 2000Mar 4, 2009Wockhardt Limited(s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
EP2033951A2Jan 31, 2003Mar 11, 2009Euro-Celtique S.A.2-Piperazine-pyridines useful for treating pain
EP2036553A1Oct 24, 2003Mar 18, 2009Celgene CorporationMethods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
EP2065383A1Nov 19, 2004Jun 3, 2009Signal Pharmaceuticals, Inc.Indazole compounds and methods of use thereof as protein kinase inhibitors
EP2067776A1Jul 23, 2004Jun 10, 2009Euro-Celtique S.A.Piperidine compounds and pharmaceutical compositions containing them
EP2074995A1Mar 20, 2003Jul 1, 2009Celgene Corporation(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP2077112A1Nov 4, 2004Jul 8, 2009Celgene CorporationMethods and compositions using thalidomide for the treatment and management of cancers and idiopathic pulmonary fibrosis
EP2087891A2May 16, 2003Aug 12, 2009Celgene CorporationPharmaceutical compositions for treating lymphoma
EP2096107A1Dec 23, 2004Sep 2, 2009GPC Biotech AGDerivatives of squaric acid with anti-proliferative activity
EP2105135A2May 16, 2003Sep 30, 2009Celgene CorporationPharmaceutical compositions for treating cancer
EP2105136A2May 16, 2003Sep 30, 2009Celgene CorporationPharmaceutical compositions for treating cancer
EP2112150A1Apr 22, 2008Oct 28, 2009GPC Biotech AGImproved raf inhibitors
EP2112152A1Apr 22, 2008Oct 28, 2009GPC Biotech AGDihydropteridinones as Plk Inhibitors
EP2133325A1Mar 31, 2000Dec 16, 2009Sepracor Inc.Derivatives of venlafaxine and methods of preparing and using the same
EP2158903A2Dec 14, 1999Mar 3, 2010ALZA CorporationTransparent Transdermal Nicotine Delivery Devices
EP2163643A1Mar 5, 2004Mar 17, 2010Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2177620A1Mar 5, 2004Apr 21, 2010Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2194053A1Jan 7, 2005Jun 9, 2010Aryx Therapeutics, Inc.Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP2201840A1Dec 28, 2006Jun 30, 2010Pharmacyclics, Inc.Inhibitors of Bruton's Tyrosine Kinase
EP2218779A1Dec 15, 2003Aug 18, 2010Halozyme, Inc.Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
EP2223687A1Mar 20, 2003Sep 1, 2010Celgene Corporation(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
EP2223688A1Mar 20, 2003Sep 1, 2010Celgene Corporation(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
EP2258363A1May 16, 2003Dec 8, 2010Celgene CorporationCompositions for treatment of cancers
EP2272512A1May 16, 2003Jan 12, 2011Celgene CorporationPharmaceutical compositions for treating cancer
EP2272513A1May 16, 2003Jan 12, 2011Celgene CorporationPharmaceutical compositions for treating cancer
EP2280008A2Jan 15, 2008Feb 2, 2011Purdue Pharma L.P.Heterocyclic-substituted piperidines as ORL-1 ligands
EP2289497A1Nov 9, 2006Mar 2, 2011Circ Pharma Research and Development LimitedOnce-daily administration of central nervous system drugs
EP2292213A1Feb 1, 2005Mar 9, 2011Cephalon, Inc.Compositions comprising a polymorphic form of armodafinil
EP2295416A2Nov 17, 2005Mar 16, 2011Synta Pharmaceuticals Corp.Triazole compounds that modulate HSP90 activity
EP2298748A2Nov 17, 2005Mar 23, 2011Synta Pharmaceuticals Corp.Triazole compounds that modulate HSP90 activity
EP2298764A1Nov 21, 2006Mar 23, 2011Purdue Pharma LP4-Oxadiazolyl-piperidine compounds and use thereof
EP2298765A1Nov 21, 2006Mar 23, 2011Purdue Pharma LP4-Oxadiazolyl-piperidine compounds and use thereof
EP2298770A1Nov 2, 2006Mar 23, 2011ChemBridge CorporationHeterocyclic compounds as TrkA modulators
EP2298874A1Dec 15, 2003Mar 23, 2011Halozyme, Inc.Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
EP2308480A2Sep 22, 2006Apr 13, 2011ALZA CorporationHigh Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
EP2311973A1Mar 5, 2004Apr 20, 2011Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2316437A1May 12, 2006May 4, 2011Alza CorporationMultilayer drug delivery system with barrier against reservoir material flow
EP2316455A1May 16, 2003May 4, 2011Celgene CorporationPharmaceutical compositions for treating cancer
EP2319516A1Jul 22, 2004May 11, 2011Synta Pharmaceuticals Corp.Compounds for treating inflammatory and autoimmune disorders
EP2322179A1Jul 17, 2003May 18, 2011Avanir Pharmaceuticals, Inc.Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders
EP2325185A1Oct 28, 2009May 25, 2011GPC Biotech AGPlk inhibitor
EP2330213A1Mar 5, 2004Jun 8, 2011Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2339328A2Dec 24, 2003Jun 29, 2011Transform Pharmaceuticals, Inc.Pharmaceutical co-crystal compositions of celecoxib
EP2380564A2Apr 4, 2008Oct 26, 2011Sigmoid Pharma LimitedAn oral pharmaceutical composition
EP2383271A1Mar 13, 2007Nov 2, 2011Kyorin Pharmaceutical Co., Ltd.Aminoquinolones as GSK-3 Inhibitors
EP2399578A1May 11, 2006Dec 28, 2011The Interthyr CorporationMethods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
EP2405015A2Mar 5, 2004Jan 11, 2012Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP2409691A1Apr 4, 2008Jan 25, 2012Sigmoid Pharma LimitedPharmaceutical cyclosporin compositions
EP2420490A1Mar 20, 2003Feb 22, 2012Celgene Corporation(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
EP2420497A1Sep 25, 2007Feb 22, 2012Celgene Corporation5-substituted quinazolinone derivatives as anti-cancer agents
EP2420498A1Sep 25, 2007Feb 22, 2012Celgene Corporation5-substituted quinazolinone derivatives as anti-cancer agents
EP2428513A1Sep 25, 2007Mar 14, 2012Celgene Corporation5-substituted quinazolinone derivatives as anti-cancer agents
EP2433634A2Sep 16, 2005Mar 28, 2012The Whitehead Institute for Biomedical ResearchCompounds, compositions and methods of inhibiting a-synuclein toxicity
EP2433935A1Aug 29, 2008Mar 28, 2012Purdue Pharma LPSubstituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2433936A1Aug 29, 2008Mar 28, 2012Purdue Pharma LPSubstituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2433937A1Aug 29, 2008Mar 28, 2012Purdue Pharma LPSubstituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2443929A1Dec 28, 2006Apr 25, 2012Pharmacyclics, Inc.Inhibitors of Bruton's Tyrosine Kinase
EP2460522A2May 5, 2004Jun 6, 2012Celgene CorporationMethods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP2471518A2May 18, 2010Jul 4, 2012Sigmoid Pharma LimitedComposition comprising oil drops
EP2476690A1Jul 1, 2009Jul 18, 2012IDENIX Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
EP2479173A1Apr 25, 2008Jul 25, 2012Purdue Pharma LPTherapeutic agents useful for treating pain
EP2500337A2Feb 21, 2008Sep 19, 2012Sepracor Inc.Solid form comprising (-) o-desmethylvenlafaxine and uses thereof
EP2502921A1Apr 21, 2010Sep 26, 2012Axikin Pharmaceuticals, Inc.Arylsulfonamide CCR3 antagonists
EP2505200A1Mar 18, 2005Oct 3, 2012Celgene CorporationMethods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
EP2514740A1Mar 13, 2008Oct 24, 2012Auspex Pharmaceuticals, Inc.Deuterated O-desmethylvenlafaxines with serotoninergic and/or norepinephrinergic activity
EP2514745A1Dec 17, 2009Oct 24, 2012Metabolex Inc.GPR120 receptor agonists and uses thereof
EP2520561A1Jun 9, 2008Nov 7, 2012MannKind CorporationIRE-1A Inhibitors
EP2526771A1Dec 28, 2006Nov 28, 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2526933A2Dec 28, 2006Nov 28, 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2526934A2Dec 28, 2006Nov 28, 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2526946A1Oct 3, 2006Nov 28, 2012Celgene CorporationMethods Using 3-(4-Amino-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione For Treatment Of Certain Leukemias
EP2527315A1May 30, 2003Nov 28, 2012Proteotech Inc.Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
EP2529621A1Dec 28, 2006Dec 5, 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2529622A1Dec 28, 2006Dec 5, 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2530083A1Dec 28, 2006Dec 5, 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2532234A1Dec 28, 2006Dec 12, 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2532235A1Dec 28, 2006Dec 12, 2012Pharmacyclics, Inc.Inhibitors of bruton's tyrosine kinase
EP2532643A1Jun 9, 2008Dec 12, 2012MannKind CorporationIRE-1A Inhibitors
EP2537844A1Jul 20, 2009Dec 26, 2012Purdue Pharma L.P.Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EP2561872A1Dec 16, 2005Feb 27, 2013Anadys Pharmaceuticals, Inc.3, 5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof
EP2561874A2May 16, 2003Feb 27, 2013Celgene CorporationPharmaceutical compositions for treating cancer
EP2572712A2Jun 2, 2008Mar 27, 2013The Trustees Of Princeton UniversityTreatment of viral infections by modulation of host cell metabolic pathways
EP2586428A1Apr 25, 2008May 1, 2013Sigmoid Pharma LimitedManufacture of multiple minicapsules
EP2604598A1Apr 25, 2008Jun 19, 2013Purdue Pharma L.P.TRPV1 antagonists and uses thereof
EP2604599A1Apr 25, 2008Jun 19, 2013Purdue Pharma LPTRPV1 antagonists and uses thereof
EP2617423A1Oct 19, 2007Jul 24, 2013Genzyme CorporationPurine derivatives for the treatment of cystic diseases
EP2617704A1Jun 2, 2008Jul 24, 2013Sepracor Inc.Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2650294A1Oct 12, 2010Oct 16, 2013Pharmacyclics, Inc.Inhibitors of Bruton's Tyrosine Kinase
EP2662090A1Apr 14, 2009Nov 13, 2013Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP2664337A1Sep 27, 2006Nov 20, 2013TissueTech, Inc.Amniotic membrane preparations and purified compositions and methods of use
EP2687213A1Mar 27, 2008Jan 22, 2014Celgene CorporationSolid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2690095A1Oct 20, 2009Jan 29, 2014Camabay Therapeutics, Inc.Aryl gpr120 receptor agonists and uses thereof
EP2695616A1Mar 27, 2008Feb 12, 2014Celgene CorporationSolid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2703404A1Jul 30, 2009Mar 5, 2014Purdue Pharma L.P.Buprenorphine analogs
EP2727908A2Apr 21, 2010May 7, 2014Axikin Pharmaceuticals, Inc.2,5-disubstituted arylsulfonamide CCR3 antagonists
WO1980001041A1 *Nov 15, 1979May 29, 1980D SeymourAdhesive-coated sheet material incorporating anti-bacterial substances
WO1987000042A1 *Jun 27, 1986Jan 15, 1987Univ New JerseyTransdermal verapamil delivery device
WO1987001938A1 *Sep 11, 1986Apr 9, 1987Univ CaliforniaLiposome transdermal drug delivery system
WO1987007138A1 *May 29, 1987Dec 3, 1987Univ RutgersTransdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
WO1998055043A1Apr 27, 1998Dec 10, 1998Gillette CanadaDental hygiene article
WO2003022259A1Sep 12, 2002Mar 20, 2003Sepracor IncMethods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
WO2003077847A2Mar 7, 2003Sep 25, 2003Helen M ArmstrongSubstituted amides
WO2003101927A1May 30, 2003Dec 11, 2003Proteotech IncCompounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
WO2004009558A2Jul 23, 2003Jan 29, 2004Ptc Therapeutics IncUreido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2004078161A1Sep 4, 2003Sep 16, 2004Transform Pharmaceuticals IncPharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004081001A1Feb 13, 2004Sep 23, 2004Banyu Pharma Co LtdNovel 2-pyridinecarboxamide derivatives
WO2005009539A2Jul 22, 2004Feb 3, 2005Synta Pharmaceuticals CorpCompounds for inflammation and immune-related uses
WO2005066126A1Dec 13, 2004Jul 21, 2005Lilly Co EliCb1 modulator compounds
WO2005089767A1Mar 10, 2005Sep 29, 2005Barton Aron KamenUse of aminopterin for treating cancer and inflammatory disorders
WO2005099569A1 *Apr 7, 2005Oct 27, 2005Abbott LabArticle and method for applying a coupling agent for a non-invasive optical probe
WO2006049304A1Nov 1, 2005May 11, 2006Banyu Pharma Co LtdAryloxy-substituted benzimidazole derivatives
WO2006066074A2Dec 15, 2005Jun 22, 2006Univ CaliforniaLung-targeted drugs
WO2006081391A2Jan 25, 2006Aug 3, 2006Synta Pharmaceuticals CorpCompounds for inflammation and immune-related uses
WO2006119365A2May 2, 2006Nov 9, 2006Cold Spring Harbor LabComposition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2007013929A1Jul 20, 2006Feb 1, 2007Amgen IncAniline sulfonamide derivatives and their uses
WO2007027527A2Aug 25, 2006Mar 8, 2007Celgene CorpIsoindole-imide compounds and compositions comprising and methods of using the same
WO2007028073A2Aug 31, 2006Mar 8, 2007Aryx TherapeuticsSynthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007033112A1Sep 12, 2006Mar 22, 2007Celgene CorpMethods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2007035939A2Sep 22, 2006Mar 29, 2007Alza CorpHigh enhancer-loading polyacrylate formulation for transdermal applications
WO2007037534A1Sep 29, 2006Apr 5, 2007Banyu Pharma Co Ltd2-heteroaryl-substituted indole derivative
WO2007062266A2Nov 28, 2006May 31, 2007Marinus PharmaceuticalsGanaxolone formulations and methods for the making and use thereof
WO2007087442A2Jan 25, 2007Aug 2, 2007Synta Pharmaceuticals CorpSubstituted biaryl compounds for inflammation and immune-related uses
WO2007087443A2Jan 25, 2007Aug 2, 2007Synta Pharmaceuticals CorpVinyl-phenyl derivatives for inflammation and immune-related uses
WO2007089904A2Jan 31, 2007Aug 9, 2007Synta Pharmaceuticals CorpPyridylphenyl compounds for inflammation and immune-related uses
WO2007150002A2Jun 21, 2007Dec 27, 2007Anadys Pharmaceuticals IncPRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE
WO2008011406A2Jul 17, 2007Jan 24, 2008Anadys Pharmaceuticals IncCarbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2008019065A1Aug 2, 2007Feb 14, 2008Celgene CorpUse of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
WO2008021368A2Aug 13, 2007Feb 21, 2008Norman HaugheyCompositions and methods for neuroprotection
WO2008021369A2Aug 13, 2007Feb 21, 2008Chembridge Res Lab IncTricyclic compounds and its use as tyrosine kinase modulators
WO2008027542A2Aug 29, 2007Mar 6, 2008Celgene Corp5-substituted isoindoline compounds
WO2008039489A2Sep 25, 2007Apr 3, 2008Celgene Corp5-substituted quinazolinone derivatives as antitumor agents
WO2008039520A2Sep 26, 2007Apr 3, 2008Synta Pharmaceuticals CorpFused ring compounds for inflammation and immune-related uses
WO2008044777A1Oct 5, 2007Apr 17, 2008Masanori Asai2-pyridinecarboxamide derivative having gk-activating activity
WO2008049116A2Oct 19, 2007Apr 24, 2008Auspex Pharmaceuticals IncSubstituted indoles
WO2008066131A1Nov 29, 2007Jun 5, 2008Banyu Pharma Co LtdNovel phenyl-isoxazol-3-ol derivative
WO2008066899A2Nov 28, 2007Jun 5, 2008Marinus PharmaceuticalsNanoparticulate formulations and methods for the making and use thereof
WO2008094476A1Jan 25, 2008Aug 7, 2008Merck & Co IncSubstituted pyrano [2, 3 - b] pyridine derivatives as cannabinoid -1 receptor modulators
WO2008106166A2Feb 27, 2008Sep 4, 2008Conatus Pharmaceuticals IncMethods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
WO2008122965A2Apr 4, 2008Oct 16, 2008Sigmoid Pharma LtdPharmaceutical cyclosporin compositions
WO2008122967A2Apr 4, 2008Oct 16, 2008Sigmoid Pharma LtdAn oral pharmaceutical composition
WO2009017818A1Jul 31, 2008Feb 5, 2009Synta Pharmaceuticals CorpHeterocycle-aryl compounds for inflammation and immune-related uses
WO2009017831A1Jul 31, 2008Feb 5, 2009Synta Pharmaceuticals CorpVinyl-aryl derivatives for inflammation and immune-related uses
WO2009042177A1Sep 25, 2008Apr 2, 2009Celgene Corp6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2009063821A1Nov 10, 2008May 22, 2009Banyu Pharma Co LtdHeteroaryloxy quinazoline derivative
WO2009081782A1Dec 15, 2008Jul 2, 2009Banyu Pharma Co LtdN-pyrazole-2-pyridinecarboxamide derivative
WO2009147990A1May 28, 2009Dec 10, 2009Banyu Pharmaceutical Co.,Ltd.Novel isoxazole derivative
WO2010014229A1Jul 30, 2009Feb 4, 2010Purdue Pharma L.P.Buprenorphine analogs
WO2010027975A1Sep 1, 2009Mar 11, 2010Anacor Pharmaceuticals, Inc.Boron-containing small molecules
WO2010039308A1Jun 26, 2009Apr 8, 2010Proteotech Inc.COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF β-AMYLOID DISEASES AND SYNUCLEINOPATHIES
WO2010042834A1Oct 9, 2009Apr 15, 2010Anadys Pharmaceuticals, Inc.A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
WO2010071866A2Dec 19, 2009Jun 24, 2010Nuon Therapeutics, Inc.Combination therapy for arthritis with tranilast
WO2010075064A1Dec 15, 2009Jul 1, 2010Sepracor Inc.Triple reuptake inhibitors and methods of their use
WO2010075255A2Dec 21, 2009Jul 1, 2010Sloan-Kettering Institute For Cancer ResearchMethods for treating or preventing cancer and neurodegenerative diseases
WO2010075280A2Dec 21, 2009Jul 1, 2010Sloan-Kettering Institute For Cancer ResearchCoumarin-based compounds
WO2010076329A1Dec 30, 2009Jul 8, 2010Scynexis, Inc.Derivatives of cyclosporin a
WO2010077297A1Dec 9, 2009Jul 8, 2010Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
WO2010088450A2Jan 29, 2010Aug 5, 2010Celladon CorporationMethods for treating diseases associated with the modulation of serca
WO2010093425A1Feb 11, 2010Aug 19, 2010Sepracor Inc.Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2010093434A1Feb 9, 2010Aug 19, 2010Celgene CorporationIsotopologues of lenalidomide
WO2010093588A1Feb 9, 2010Aug 19, 2010Celgene CorporationMethods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
WO2010095767A1Feb 22, 2010Aug 26, 2010Banyu Pharmaceutical Co.,Ltd.Pyrimidin-4(3h)-one derivatives
WO2010099379A1Feb 26, 2010Sep 2, 2010Ambit Biosciences CorporationJak kinase modulating quinazoline derivatives and methods of use thereof
WO2010101967A2Mar 3, 2010Sep 10, 2010Idenix Pharmaceuticals, Inc.Phosphothiophene and phosphothiazole hcv polymerase inhibitors
WO2010102262A1Mar 5, 2010Sep 10, 2010Halozyme, Inc.Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
WO2010104195A1Mar 9, 2010Sep 16, 2010Banyu Pharmaceutical Co.,Ltd.Novel isoindolin-1-one derivative
WO2010105016A1Mar 11, 2010Sep 16, 2010Ambit Biosciences Corp.Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
WO2010110685A2Mar 26, 2010Sep 30, 2010Pathway Therapeutics LimitedPyrimddinyl and 1,3,5-triazinyl benzimtoazole sulfonamides and their use in cancer therapy
WO2010110686A1Mar 26, 2010Sep 30, 2010Pathway Therapeutics LimitedPyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
WO2010127452A1May 4, 2010Nov 11, 2010The Royal Institution For The Advancement Of Learning/Mcgill University5-oxo-ete receptor antagonist compounds
WO2010144571A1Jun 9, 2010Dec 16, 2010Sepracor Inc.Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011003870A2Jul 5, 2010Jan 13, 2011Creabilis S.A.Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
WO2011005119A1Jul 6, 2010Jan 13, 2011Pathway Therapeutics LimitedPyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011009961A1Jul 26, 2010Jan 27, 2011Virologik GmbhCombination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
WO2011014775A1Jul 30, 2010Feb 3, 2011The Brigham And Women's Hospital, Inc.Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
WO2011017389A1Aug 4, 2010Feb 10, 2011Idenix Pharmaceuticals, Inc.Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011018504A2Aug 12, 2010Feb 17, 2011Sigmoid Pharma LimitedImmunomodulatory compositions comprising a polymer matrix and an oil phase
WO2011022473A1Aug 18, 2010Feb 24, 2011Ambit Biosciences CorporationBiaryl compounds and methods of use thereof
WO2011031816A2Sep 9, 2010Mar 17, 2011Sepracor Inc.Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011031818A2Sep 9, 2010Mar 17, 2011Sepracor Inc.Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011041154A1Sep 20, 2010Apr 7, 2011Metabolex, Inc.Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011042482A1Oct 6, 2010Apr 14, 2011Green MolecularPolyphenols for use in the treatment of cancer
WO2011049946A1Oct 19, 2010Apr 28, 2011Synta Pharmaceuticals Corp.Combination cancer therapy with hsp90 inhibitory compounds
WO2011056566A2Oct 26, 2010May 12, 2011Sunesis Pharmaceuticals, Inc.Compounds and methods for treatment of cancer
WO2011056764A1Nov 2, 2010May 12, 2011Ambit Biosciences Corp.Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011063076A1Nov 18, 2010May 26, 2011Itherx Pharmaceuticals, Inc.Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011063102A1Nov 18, 2010May 26, 2011Celgene CorporationApremilast for the treatment of sarcoidosis
WO2011064769A1Nov 22, 2010Jun 3, 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and pharmaceutical compositions for the treatment of hot flashes
WO2011069002A1Dec 2, 2010Jun 9, 2011Alquest Therapeutics, Inc.Organoselenium compounds and uses thereof
WO2011070364A1Dec 9, 2010Jun 16, 2011Scynexis, Inc.Novel cyclic peptides
WO2011075615A1Dec 17, 2010Jun 23, 2011Idenix Pharmaceuticals, Inc.5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011079091A1Dec 21, 2010Jun 30, 2011Celgene Corporation(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
WO2011082289A1Dec 30, 2010Jul 7, 2011Scynexis Inc.Cyclosporine analogues
WO2011089166A1Jan 19, 2011Jul 28, 2011Virologik GmbhSemicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2011089167A1Jan 19, 2011Jul 28, 2011Virologik GmbhKombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011100380A1Feb 10, 2011Aug 18, 2011Celgene CorporationArylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2011109345A1Mar 1, 2011Sep 9, 2011Axikin Pharmaceuticals, Inc.Isotopically enriched arylsulfonamide ccr3 antagonists
WO2011112689A2Mar 9, 2011Sep 15, 2011Ambit Biosciences Corp.Saltz of an indazolylpyrrolotriazine
WO2011112933A1Mar 11, 2011Sep 15, 2011Celgene CorporationMethods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
WO2011116161A2Mar 17, 2011Sep 22, 2011Axikin Pharmaceuticals Inc.Arylsulfonamide ccr3 antagonists
WO2011127019A2Apr 5, 2011Oct 13, 2011Celgene CorporationMethods for treating respiratory viral infection
WO2011127070A2Apr 5, 2011Oct 13, 2011Mannkind CorporationIRE-1α INHIBITORS
WO2011133520A1Apr 19, 2011Oct 27, 2011Synta Pharmaceuticals Corp.Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011133521A2Apr 19, 2011Oct 27, 2011Synta Pharmaceuticals Corp.Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
WO2011143147A1May 10, 2011Nov 17, 2011Celgene CorporationMethods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
WO2011146803A1May 20, 2011Nov 24, 2011Synta Pharmaceuticals Corp.Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
WO2011149824A1May 23, 2011Dec 1, 2011Synta Pharmaceuticals Corp.Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2011150183A1May 26, 2011Dec 1, 2011Ge Healthcare LimitedRadiolabeled compounds and methods thereof
WO2011150198A1May 26, 2011Dec 1, 2011Ambit Biosciences CorporationAzolyl urea compounds and methods of use thereof
WO2011150201A2May 26, 2011Dec 1, 2011Ambit Biosciences CorporationAzolyl amide compounds and methods of use thereof
WO2011153197A1Jun 1, 2011Dec 8, 2011Biotheryx, Inc.Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
WO2011153199A1Jun 1, 2011Dec 8, 2011Biotheryx, Inc.Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
WO2011156321A1Jun 7, 2011Dec 15, 2011Novomedix, LlcFuranyl compounds and the use thereof
WO2011159297A1Jun 16, 2010Dec 22, 2011Metabolex, Inc.Gpr120 receptor agonists and uses thereof
WO2012012370A1Jul 19, 2011Jan 26, 2012Summa Health SystemVitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
WO2012025217A1Aug 23, 2011Mar 1, 2012Algiax Pharmaceuticals GmbhNovel use of leflunomide and malononitrilamides
WO2012030885A1Aug 31, 2011Mar 8, 2012Ambit Biosciences CorporationHydrobromide salts of a pyrazolylaminoquinazoline
WO2012030894A1Aug 31, 2011Mar 8, 2012Ambit Biosciences CorporationThienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012030910A1Aug 31, 2011Mar 8, 2012Ambit Biosciences Corporation2-cycloquinazoline derivatives and methods of use thereof
WO2012030912A1Aug 31, 2011Mar 8, 2012Ambit Biosciences Corporation7-cyclylquinazoline derivatives and methods of use thereof
WO2012030913A1Aug 31, 2011Mar 8, 2012Ambit Biosciences CorporationAn optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030914A1Aug 31, 2011Mar 8, 2012Ambit Boisciences Corporation4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012030917A1Aug 31, 2011Mar 8, 2012Ambit Biosciences CorporationAn optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030918A1Aug 31, 2011Mar 8, 2012Ambit Biosciences CorporationAdenosine a3 receptor modulating compounds and methods of use thereof
WO2012030924A1Aug 31, 2011Mar 8, 2012Ambit Biosciences CorporationAzolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030944A2Aug 31, 2011Mar 8, 2012Ambit Biosciences CorporationQuinoline and isoquinoline compounds and methods of use thereof
WO2012030948A1Aug 31, 2011Mar 8, 2012Ambit Biosciences CorporationQuinazoline compounds and methods of use thereof
WO2012037072A1Sep 13, 2011Mar 22, 2012Synta Pharmaceuticals CorporationHsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
WO2012044641A1Sep 28, 2011Apr 5, 2012Pathway Therapeutics Inc.1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1Oct 10, 2011Apr 19, 2012Axikin Pharmaceuticals, Inc.Salts of arylsulfonamide ccr3 antagonists
WO2012055567A2Oct 28, 2011May 3, 2012Algiax Pharmaceuticals GmbhUse of malononitrilamides in neuropathic pain
WO2012064808A1Nov 9, 2011May 18, 2012Synta Pharmaceuticals CorpTetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
WO2012069658A2Nov 25, 2011May 31, 2012Sigmoid Pharma LimitedImmunomodulatory compositions
WO2012078492A1Dec 5, 2011Jun 14, 2012Celgene CorporationA combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2012078757A2Dec 7, 2011Jun 14, 2012Synta Pharmaceuticals Corp.Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012080050A1Dec 7, 2011Jun 21, 2012Conatus Pharmaceuticals Inc.Solid forms of a phenoxybenzenesulfonyl compound
WO2012083017A2Dec 15, 2011Jun 21, 2012Celgene CorporationControlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012085648A1Dec 21, 2011Jun 28, 2012Purdue Pharma L.P.Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
WO2012096884A1Jan 9, 2012Jul 19, 2012Celgene CorporationPhenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
WO2012096919A1Jan 10, 2012Jul 19, 2012Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2012106299A1Jan 31, 2012Aug 9, 2012Celgene CorporationPharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012109398A1Feb 9, 2012Aug 16, 2012Idenix Pharmaceuticals, Inc.Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012115723A1Jan 6, 2012Aug 30, 2012Medtronic, Inc.Emergency mode switching for non-pacing modes
WO2012116061A1Feb 22, 2012Aug 30, 2012Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitory compounds with radiotherapy
WO2012116247A1Feb 24, 2012Aug 30, 2012Synta Pharmaceuticals Corp.Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2012121988A2Mar 2, 2012Sep 13, 2012Celgene CorporationMethods for treating diseases using isoindoline compounds
WO2012123353A1Mar 9, 2012Sep 20, 2012Algiax Pharmaceuticals GmbhNovel use of benzofuranylsulfonates
WO2012123406A1Mar 12, 2012Sep 20, 2012Algiax Pharmaceuticals GmbhNovel use of imidazotriazinones
WO2012125438A1Mar 9, 2012Sep 20, 2012Celgene CorporationSolid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2012125459A1Mar 9, 2012Sep 20, 2012Celgene CorporationMethods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
WO2012125475A1Mar 9, 2012Sep 20, 2012Celgene CorporationUse of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
WO2012129237A2Mar 20, 2012Sep 27, 2012The University Of British ColumbiaTherapeutic agent for emphysema and copd
WO2012135160A1Mar 27, 2012Oct 4, 2012Pathway Therapeutics Inc.(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2012135166A1Mar 27, 2012Oct 4, 2012Pathway Therapeutics Inc.(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135175A1Mar 27, 2012Oct 4, 2012Pathway Therapeutics Inc.(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135581A1Mar 30, 2012Oct 4, 2012Idenix Pharmaceuticals, Inc.Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012141796A2Feb 23, 2012Oct 18, 2012Synta Pharmaceuticals Corp.Prostate cancer therapy with hsp90 inhibitory compounds
WO2012149251A1Apr 27, 2012Nov 1, 2012Celgene CorporationMethods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
WO2012149299A2Apr 27, 2012Nov 1, 2012Celgene CorporaitonMethods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2012151474A2May 4, 2012Nov 8, 2012Trustees Of Boston UniversityProton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
WO2012154321A1Mar 30, 2012Nov 15, 2012Centre National De La Recherche ScientifiqueCompounds and pharmaceutical compositions for the treatment of viral infections
WO2012158271A1Apr 5, 2012Nov 22, 2012Anadys Pharmaceuticals, Inc.Bridged polycyclic compounds as antiviral agents
WO2012162372A1May 23, 2012Nov 29, 2012Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
WO2012169934A1May 31, 2012Dec 13, 2012Asinex LimitedNovel kinase inhibitors
WO2012176061A1Jun 21, 2012Dec 27, 2012Purdue Pharma L.P.Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2012177678A2Jun 20, 2012Dec 27, 2012Celgene CorporationIsotopologues of pomalidomide
WO2013006864A2Jul 9, 2012Jan 10, 2013Synta Pharmaceuticals Corp.Treating cancer with hsp90 inhibitory compounds
WO2013014274A1Jul 27, 2012Jan 31, 2013Ge Healthcare Limited5ht1a antagonist useful for in vivo imaging
WO2013021276A1Aug 9, 2012Feb 14, 2013Purdue Pharma L.P.Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013022872A1Aug 7, 2012Feb 14, 2013Celgene CorporationGene methylation biomarkers and methods of use thereof
WO2013024040A2Aug 10, 2012Feb 21, 2013B.S.R.C. Alexander FlemingTnf superfamily trimerization inhibitors
WO2013028505A1Aug 17, 2012Feb 28, 2013Synta Pharmaceuticals Corp.Combination cancer therapy of hsp90 inhibitor with antimetabolite
WO2013028880A1Aug 23, 2012Feb 28, 2013Cornerstone Therapeutics Inc.Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
WO2013032591A1Jul 18, 2012Mar 7, 2013Infinity Pharmaceuticals Inc.Heterocyclic compounds and uses thereof
WO2013039855A1Sep 11, 2012Mar 21, 2013Idenix Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039920A1Sep 11, 2012Mar 21, 2013Idenix Pharmaceuticals, Inc.Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013043967A1Sep 21, 2012Mar 28, 2013Celgene CorporationRomidepsin and 5 - azacitidine for use in treating lymphoma
WO2013049093A1Sep 26, 2012Apr 4, 2013Celgene CorporationCombination therapy for chemoresistant cancers
WO2013049332A1Sep 27, 2012Apr 4, 2013Infinity Pharmaceuticals, Inc.Inhibitors of monoacylglycerol lipase and methods of their use
WO2013056046A1Oct 12, 2012Apr 18, 2013Idenix Pharmaceuticals, Inc.Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056070A2Oct 12, 2012Apr 18, 2013Ambit Biosciences CorporationHeterocyclic compounds and methods of use thereof
WO2013067043A1Oct 31, 2012May 10, 2013Celgene CorporationMethods for treating cancers using oral formulations of cytidine analogs
WO2013067162A1Nov 1, 2012May 10, 2013Synta Pharmaceuticals Corp.Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013067165A1Nov 1, 2012May 10, 2013Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013071049A1Nov 9, 2012May 16, 2013Trustees Of Boston CollegeGramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2013074594A1Nov 14, 2012May 23, 2013Synta Pharmaceuticals Corp.Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013080036A1Nov 30, 2012Jun 6, 2013Purdue Pharma L.P.Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
WO2013084060A1Dec 7, 2012Jun 13, 2013Purdue Pharma L.P.Quaternized buprenorphine analogs
WO2013085902A1Dec 4, 2012Jun 13, 2013The University Of Texas M.D.Combination therapy methods for treating an inflammatory breast cancer
WO2013101926A1Dec 27, 2012Jul 4, 2013Allergan, Inc.Benzimidazole derivatives as selective blockers of persistent sodium current
WO2013103384A1Jul 11, 2012Jul 11, 2013Elcelyx Therapeutics, Inc.Biguanide compositions and methods of treating metabolic disorders
WO2013103919A2Jan 5, 2013Jul 11, 2013Elcelyx Therapeutics, Inc.Compositions and methods for treating metabolic disorders
WO2013126394A1Feb 20, 2013Aug 29, 2013Celgene CorporationSolid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
WO2013130600A1Feb 27, 2013Sep 6, 2013Ambit Biosciences CorporationSolid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A1Mar 7, 2013Sep 12, 2013Stichting Vu-VumcCompositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
WO2013138613A1Mar 14, 2013Sep 19, 2013Axikin Pharmaceuticals, Inc.3,5-diaminopyrazole kinase inhibitors
WO2013138617A1Mar 14, 2013Sep 19, 2013Axikin Pharmaceuticals, Inc.3,5-diaminopyrazole kinase inhibitors
WO2013142380A1Mar 15, 2013Sep 26, 2013The Regents Of The University Of CaliforniaOncovector nucleic acid molecules and methods of use
WO2013148857A1Mar 27, 2013Oct 3, 2013Synta Pharmaceuticals Corp.Triazole derivatives as hsp90 inhibitors
WO2013148864A1Mar 27, 2013Oct 3, 2013Andrei GudkovCuraxins for use in treating breast cancer and method for identifying patients likely to respond
WO2013152206A1Apr 4, 2013Oct 10, 2013Synta Pharmaceuticals Corp.Novel triazole compounds that modulate hsp90 activity
WO2013154878A1Apr 3, 2013Oct 17, 2013Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
WO2013156231A1Mar 18, 2013Oct 24, 2013Algiax Pharmaceuticals GmbhUse of imidazotriazinones in neuropathic pain
WO2013156232A1Mar 18, 2013Oct 24, 2013Algiax Pharmaceuticals GmbhUse of benzofuranylsulfonates in neuropathic pain
WO2013156850A1Apr 17, 2013Oct 24, 2013Purdue Pharma L.P.Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2013158928A2Apr 18, 2013Oct 24, 2013Elcelyx Therapeutics, Inc.Chemosensory receptor ligand-based therapies
WO2013167963A1May 10, 2013Nov 14, 2013Purdue Pharma L.P.Benzomorphan compounds as opioid receptors modulators
WO2013170159A1May 10, 2013Nov 14, 2013Synta Pharmaceuticals Corp.Treating cancer with hsp90 inhibitory compounds
WO2013177188A1May 21, 2013Nov 28, 2013Idenix Pharmaceuticals, Inc.3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177195A1May 21, 2013Nov 28, 2013Idenix Pharmaceuticals, Inc.3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177219A1May 21, 2013Nov 28, 2013Idenix Pharmaceuticals, Inc.D-amino acid compounds for liver disease
WO2014006215A1Jul 5, 2013Jan 9, 2014Sigmoid Pharma LimitedHydrogel vaccine formulations
WO2014020405A1Jul 29, 2013Feb 6, 2014Purdue Pharma L.P.Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
WO2014025960A1Aug 8, 2013Feb 13, 2014Celgene CorporationMethods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
WO2014030053A1Aug 20, 2013Feb 27, 2014Rhodes TechnologiesSystems and methods for increasing stability of dronabinol compositions
WO2014033530A1Aug 27, 2013Mar 6, 2014Rhodes Technologies1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014039748A1Sep 6, 2013Mar 13, 2014Axikin Pharmaceuticals, Inc.Isotopically enriched arylsulfonamide ccr3 antagonists
WO2014039960A1Sep 9, 2013Mar 13, 2014Celgene CorporationMethods for the treatment of locally advanced breast cancer
WO2014055647A1Oct 2, 2013Apr 10, 2014Mei Pharma, Inc.(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2014058801A1Oct 7, 2013Apr 17, 2014Idenix Pharmaceuticals, Inc.2'-chloro nucleoside analogs for hcv infection
WO2014063019A1Oct 18, 2013Apr 24, 2014Idenix Pharmaceuticals, Inc.Dinucleotide compounds for hcv infection
WO2014071109A1Nov 1, 2013May 8, 2014Infinity Pharmaceuticals, Inc.Treatment of cancers using pi3 kinase isoform modulators
WO2014072809A2Nov 8, 2013May 15, 2014Purdue Pharma L.P.Benzomorphan analogs and the use thereof
WO2014074765A2Nov 8, 2013May 15, 2014Summa Health SystemVitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
WO2014074846A1Nov 8, 2013May 15, 2014Celgene CorporationMethods for the treatment of bone loss
WO2014078427A1Nov 13, 2013May 22, 2014Idenix Pharmaceuticals, Inc.D-alanine ester of rp-nucleoside analog
WO2014078436A1Nov 13, 2013May 22, 2014Idenix Pharmaceuticals, Inc.D-alanine ester of sp-nucleoside analog
WO2014085284A1Nov 25, 2013Jun 5, 2014Sunovion Pharmaceuticals Inc.Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
WO2014085633A1Nov 27, 2013Jun 5, 2014Novomedix, LlcSubstituted biaryl sulfonamides and the use thereof
WO2014087226A1Dec 4, 2013Jun 12, 2014Purdue Pharma L.P.Buprenorphine analogs as opiod receptor modulators
WO2014091295A1Dec 13, 2013Jun 19, 2014Purdue Pharma L.P.Pyridonemorphinan analogs and biological activity on opioid receptors
WO2014091297A1Dec 13, 2013Jun 19, 2014Purdue Pharma L.P.Spirocyclic morphinans and their use
WO2014091298A2Dec 13, 2013Jun 19, 2014Purdue Pharma L.P.Nitrogen containing morphinan derivatives and the use thereof
WO2014093189A1Dec 9, 2013Jun 19, 2014Merck Sharp & Dohme Corp.Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
Classifications
U.S. Classification424/435, 424/449, 604/304, 401/132, 424/448
International ClassificationA61L15/58, A61L15/16, A61K9/70
Cooperative ClassificationA61K9/7061, A61L15/58, A61K9/7092, A61K9/7069
European ClassificationA61L15/58, A61K9/70E2B6D, A61K9/70E2B6B2, A61K9/70E2K